PROSPECTUS
SUPPLEMENT
|
|
Filed
Pursuant to Rule 424(b)(5)
|
(To
prospectus dated June 20, 2019)
|
|
Registration
No. 333-232229
|
NAKED
BRAND GROUP LIMITED
Up to US$18,500,000 of ordinary shares
We have entered into an amendment to our
equity distribution agreement (as amended, the “Sales Agreement”) with Maxim Group LLC (“Maxim”)
relating to the sale of our ordinary shares, without par value (“Ordinary Shares”). In accordance with the terms of
the Sales Agreement, under this prospectus supplement we may offer and sell, from time to time, Ordinary Shares having an aggregate
offering price of up to US$18,500,000, through Maxim, acting as our exclusive sales agent.
The Ordinary Shares to which this prospectus
supplement relates include the shares of common stock having an aggregate offering price of up to $5,000,000 offered pursuant
to an earlier prospectus supplement dated August 20, 2020. Of those shares of common stock, through September 24, 2020,
we have offered and sold shares of common stock having an aggregate offering price of US$3,617,219 pursuant to the prospectus
supplement dated August 20, 2020. As such, shares of common stock having an aggregate
offering price of US$14,882,781 remain available for offer and sale pursuant to this prospectus supplement. This prospectus supplement
supersedes the earlier prospectus supplement dated August 20, 2020 in its entirety.
Sales of Ordinary Shares, if any,
under this prospectus supplement and accompanying prospectus will be made by any method permitted that is deemed an “at
the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (“Securities Act”).
Maxim is not required to sell any specific amount but will act as our exclusive sales agent using commercially reasonable efforts
consistent with its normal trading and sales practices, on mutually agreed terms between Maxim and us. There is no arrangement
for funds to be received in any escrow, trust or similar arrangement.
The compensation to Maxim for the sales of
Ordinary Shares sold under the Sales Agreement will be 3% of the gross proceeds that we receive from the sales. We also reimbursed
Maxim US$45,000 for its costs and expenses relating to the Sales Agreement, including legal expenses and paid US$10,000
for background checks of our directors and officers. Because there is no minimum offering amount required as a condition to
close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at
this time. See “Plan of Distribution” beginning on page S-13 for additional information regarding the compensation
to be paid to Maxim. In connection with the sale of the Ordinary Shares on our behalf, Maxim will be deemed to be an underwriter
within the meaning of the Securities Act and the compensation of Maxim will be deemed to be underwriting commissions or discounts.
We have also agreed to provide indemnification and contribution to Maxim with respect to certain liabilities, including liabilities
under the Securities Act.
Our Ordinary Shares trade on the Capital Market
of The Nasdaq Stock Market (“Nasdaq”) under the symbol “NAKD”. The last sale price of our Ordinary Shares
on September 24, 2020 was US$0.12 per share.
As of the date of this prospectus
supplement, the aggregate market value of our outstanding voting common equity (i.e., our Ordinary Shares) held by
non-affiliates is US$55,724,261 based on a last sale price of US$0.5787 per Ordinary Share on July 27,
2020 and 96,292,140 issued and outstanding Ordinary Shares held by non-affiliates as of the date hereof. Pursuant to
General Instruction I.B.5 of Form F-3, in no event will we sell, pursuant to the registration statement of which this
prospectus supplement forms a part, securities in a public primary offering with a value exceeding one-third of the aggregate
market value of our Ordinary Shares held by non-affiliates in any 12 calendar month period, so long as the aggregate market
value of our outstanding Ordinary Shares held by non-affiliates remains below $75 million. Excluding the securities offered
hereby and by the earlier prospectus supplement dated August 20, 2020, none of our securities have been sold pursuant
to General Instruction I.B.5 of Form F-3 during the 12 calendar months prior to and including the date of this prospectus
supplement.
Investing
in our securities involves a high degree of risk. See the sections entitled “Risk Factors” beginning on page S-7 of
this prospectus supplement, on page 8 of the accompanying base prospectus and in the reports incorporated by reference herein,
for a discussion of information that should be considered in connection with an investment in our securities.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.
Maxim
Group LLC
Prospectus
Supplement dated September 25, 2020
TABLE
OF CONTENTS
BASE PROSPECTUS
You
should rely only on the information contained in this prospectus supplement, the base prospectus, and the documents we incorporate
by reference in this prospectus supplement and the base prospectus. We have not authorized anyone to provide you with different
information. We do not take any responsibility for, and cannot provide any assurance as to the reliability of, any other information
that others may give you. We are not making an offer to sell the Ordinary Shares in any jurisdiction where the offer or sale thereof
is not permitted. The information contained in this prospectus supplement and the base prospectus and incorporated by reference
herein and therein is accurate only as of the respective date of such information, regardless of the time of delivery of this
prospectus supplement or of any sale or offer to sell hereunder.
To
the extent this prospectus supplement contains summaries of the documents referred to herein, you are directed to the actual documents
for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the
documents referred to herein have been filed, will be filed, or will be incorporated by reference as exhibits to the registration
statement of which this prospectus supplement forms a part, and you may obtain copies of such documents as described below in
the section titled “Where You Can Find Additional Information.”
This
prospectus supplement contains references to a number of trademarks which are registered or for which we have pending applications
or common law rights. Our major trademarks include, among others, Bendon, Bendon Man, Davenport, Fayreform, Lovable, Pleasure
State, VaVoom, Evollove, Hickory and Frederick’s of Hollywood and other related trademarks. Solely for convenience, the
trademarks, service marks and trade names referred to in this prospectus and the documents we incorporate by reference are listed
without the ®, (sm) and (tm) symbols, but we will assert, to the fullest extent under applicable law, our rights or the rights
of the applicable licensors to these trademarks, service marks and trade names.
ABOUT
THIS PROSPECTUS SUPPLEMENT
This
prospectus supplement and the accompanying base prospectus are part of a registration statement on Form F-3 (Registration No.
333-232229) that we filed with the Securities and Exchange Commission (“SEC”) using a “shelf” registration
process. Under this “shelf” registration process, we may, from time to time, sell or issue any of the combination
of securities described in the accompanying base prospectus in one or more offerings with a maximum aggregate offering price of
up to US$30,000,000. The accompanying base prospectus provides you with a general description of us and the securities we may
offer, some of which do not apply to this offering. Each time we sell securities, we provide a prospectus supplement that contains
specific information about the terms of that offering. A prospectus supplement may also add, update, or change information contained
in the accompanying base prospectus.
This
prospectus supplement relates to the offering of our Ordinary Shares. To the extent there is a conflict between the information
contained in this prospectus supplement and the accompanying base prospectus, you should rely on the information in this prospectus
supplement. This prospectus supplement, the accompanying base prospectus, and the documents we incorporate by reference herein
and therein include important information about us and our Ordinary Shares and other information you should know before investing.
You should read both this prospectus supplement and the accompanying base prospectus, together with the additional information
described below under the heading “Where You Can Find Additional Information.”
You
should rely only on the information contained in or incorporated by reference in this prospectus supplement, the accompanying
base prospectus, and any free writing prospectus prepared by or on behalf of us or to which we have referred you. We have not,
and Maxim has not, authorized anyone to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. We are not, and Maxim is not, making an offer to sell these securities in any jurisdiction
where the offer or sale is not permitted or in which the person making that offer or solicitation is not qualified to do so or
to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus
supplement, the accompanying base prospectus, and the documents incorporated by reference herein and therein is accurate only
as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have
changed since those dates. You should carefully read this entire prospectus supplement and the accompanying base prospectus, including
the information included and referred to under “Risk Factors” below, the information incorporated by reference
in this prospectus supplement and in the accompanying base prospectus, and the financial statements and the other information
incorporated by reference in the accompanying base prospectus, before making an investment decision.
Unless
otherwise stated in this prospectus supplement, “we,” “us,” “our,” or “our company,”
refers to Naked Brand Group Limited, our subsidiaries, and our predecessor operations, “Bendon” refers to Bendon Limited,
a wholly owned subsidiary of ours, and “FOH” refers to FOH Online Corp., a wholly owned subsidiary of ours.
NOTE
ON FORWARD-LOOKING STATEMENTS
The
statements contained in this prospectus supplement and accompanying prospectus and the documents incorporated by reference herein
that are not purely historical are forward-looking statements. Forward-looking statements include, but are not limited to, statements
regarding expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer
to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions,
are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“possible,” “potential,” “predicts,” “project,” “should,” “would,”
and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement
is not forward-looking. Forward-looking statements contained in this prospectus supplement include, among other things, statements
relating to:
|
●
|
expectations
regarding industry trends and the size and growth rates of addressable markets;
|
|
|
|
|
●
|
our
business plan and our growth strategies, including plans for expansion to new markets and new products; and
|
|
|
|
|
●
|
expectations
for seasonal trends.
|
These
statements are not assurances of future performance. Instead, they are based on current expectations, assumptions, and beliefs
concerning future developments and their potential effects on us. There can be no assurance that future developments will be those
that have been assumed or anticipated. These forward-looking statements are subject to a number of risks and uncertainties (some
of which are beyond our control) that may cause our expectations, assumptions or beliefs to be inaccurate or otherwise cause our
actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, those risk factors described or incorporated by reference under
the heading “Risk Factors” and those risks described from time to time in our filings with the SEC, as well
as the following risks:
|
●
|
our
ability to raise any necessary capital;
|
|
|
|
|
●
|
our
ability to maintain the strength of our brand or to expand our brand to new products and geographies;
|
|
|
|
|
●
|
our
ability to protect or preserve our brand image and proprietary rights;
|
|
|
|
|
●
|
our
ability to satisfy changing consumer preferences;
|
|
|
|
|
●
|
an
economic downturn affecting discretionary consumer spending;
|
|
|
|
|
●
|
our
ability to compete in our markets effectively;
|
|
|
|
|
●
|
our
ability to manage our growth effectively;
|
|
|
|
|
●
|
poor
performance during our peak season affecting our operating results for the full year;
|
|
|
|
|
●
|
our
indebtedness adversely affecting our financial condition;
|
|
|
|
|
●
|
our
ability to maintain relationships with our select number of suppliers;
|
|
|
|
|
●
|
our
ability to manage our product distribution through our retail partners and international distributors;
|
|
|
|
|
●
|
the
success of our marketing programs;
|
|
|
|
|
●
|
business
interruptions because of a disruption at our headquarters;
|
|
|
|
|
●
|
fluctuations
in raw materials costs or currency exchange rates;
|
|
|
|
|
●
|
the
success of our business restructuring; and
|
|
|
|
|
●
|
the
impact of the COVID-19 pandemic.
|
Should
one or more of these risks or uncertainties materialize, or should any of our expectations, assumptions or beliefs otherwise prove
incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake
no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise,
except as may be required under applicable securities laws.
PROSPECTUS
SUPPLEMENT SUMMARY
This
summary contains basic information about us and our business but does not contain all of the information that is important to
your investment decision. Before making an investment decision, you should carefully read this summary together with the more
detailed information contained elsewhere in this prospectus supplement and the accompanying base prospectus and the documents
incorporated herein and therein by reference, including our Annual Report on Form 20-F for the fiscal year ended January 31, 2020
(the “Annual Report”). Investors should carefully consider the information set forth under the caption “Risk
Factors” appearing elsewhere in this prospectus supplement, including those described in documents incorporated by reference
herein.
On
December 20, 2019, we completed a reverse stock split of our Ordinary Shares, pursuant to which every 100 Ordinary Shares outstanding
as of the effective time of the reverse stock split were combined into one Ordinary Share. All share and per share information
in this prospectus supplement is presented on post-reverse split basis.
Overview
We
operate in the highly competitive specialty retail business. We are a designer, distributor, wholesaler, and retailer of women’s
and men’s intimate apparel, as well as women’s swimwear. Our merchandise is sold through company-owned retail stores
in Australia and New Zealand; through online channels in Australia, New Zealand and the U.S.; and through wholesale partners in
Australia and New Zealand and, on a more limited basis, through wholesale partners and distributors in the United Kingdom and
the European Union (collectively, the “E.U.”).
We
previously sold our merchandise through wholesale partners in the U.S., as well. However, in order to improve our profitability,
we have exited the U.S. wholesale market, although we continue to sell in the U.S. through online channels. We also substantially
reduced the size of our operations in the E.U. wholesale market.
Our
Brands
Bendon
Our
brands include our flagship Bendon brand, as well as our Bendon Man, Davenport, Fayreform, Lovable, Pleasure State, VaVoom, Evollove,
and Hickory brands. We sell products under these brands at 60 Bendon stores in Australia and New Zealand and online at www.bendonlingerie.com.
Additionally, we sell products under these brands in approximately 325 wholesale stores in Australia, New Zealand and the E.U.,
and through distributors in the E.U.
Frederick’s
of Hollywood
Since
1946, Frederick’s of Hollywood has set the standard for innovative apparel, introducing the push-up bra and the padded bra
to the U.S. market. The brand’s rich history has led it to become one of the most recognized in the world. Through our FOH
subsidiary, we are the exclusive licensee of the Frederick’s of Hollywood online license for the U.S., Australia and New
Zealand, under which we sell Frederick’s of Hollywood intimates products, sleepwear and loungewear products, swimwear and
swimwear accessories products, and costume products. We sell our Frederick’s of Hollywood products online at www.fredericks.com.
Former
Brands
We
previously sold products under the Stella McCartney, Heidi Klum and Naked brands. Our license to the Stella McCartney brand terminated
on June 30, 2018. On January 31, 2020, we entered into a termination agreement with Heidi Klum and Heidi Klum Company, LLC, which
provides for the termination of the license agreement between the parties. On January 28, 2020, we sold all of our right, title
and interest in the Naked brands to Gogogo SRL. We may continue selling existing Heidi Klum branded products, as well as Heidi
Klum branded products manufactured on or prior to June 30, 2020 under existing contracts. The right to continue selling such products
will continue until six months after the date of the termination agreement in the Northern Hemisphere and until 12 months after
the date of the termination agreement in the Southern Hemisphere. We also may continue selling any inventory bearing the Naked
brand that was in existence as of the closing of the sale of Naked to Gogogo SRL.
Our
Strengths
We
believe the following competitive strengths contribute to our leading market position and differentiate us from our competition:
Distinct,
Well-Recognized Brands
Our
iconic brands, including Bendon, Pleasure State, Fayreform and Frederick’s of Hollywood, have come to represent a unique
lifestyle across its targeted customers. Our brands allow us to target markets across the economic spectrum, across demographics
and across the world. We believe our flagship brands and prominent, highly-recognized creative directors provide us with a competitive
advantage.
In-Store
Experience and Store Operations
We
view our customers’ in-store experience as an important vehicle for communicating the image of each brand. We utilize visual
presentation of merchandise, in-store marketing and our sales associates to reinforce the image represented by the brands. Our
in-store marketing is designed to convey the principal elements and personality of each brand. The store design, furniture, fixtures
and music are all carefully planned and coordinated to create a unique shopping experience. Every brand displays merchandise uniformly
to ensure a consistent store experience, regardless of location. Store managers receive detailed plans designating fixture and
merchandise placement to ensure coordinated execution of the company-wide merchandising strategy. Our sales associates and managers
are a central element in creating the atmosphere of the stores by providing a high level of customer service.
Product
Development, Sourcing and Logistics
We
believe a large part of our success comes from frequent and innovative product launches, as well as launches of new collections
from our existing brands. Our merchant, design and sourcing teams have a long history of bringing innovative products to our customers.
Our key vendor partners are industry leaders in both innovation and social responsibility. We work closely together to form a
world class supply chain that is dynamic and efficient.
Highly
Experienced Leadership Team
Our
management team is led by Justin Davis-Rice, Executive Chairman, who joined Bendon in 2011 and is responsible for leading our
revenue growth. Prior to joining Bendon, Mr. Davis-Rice co-founded Pleasure State. Anna Johnson, Chief Executive Officer, brings
to us a track record of over 25 years’ experience driving growth across a number of industries, including consumer electronics,
outdoor adventure and intimate apparel. The rest of our senior management team has a wealth of retail and business experience
at The Warehouse Group, Cotton On Group and Hewlett Packard. We have developed a strong and collaborative culture aligned around
our goals to create the most beautiful, innovative lingerie that is designed to enhance comfort and fit for women all over the
world.
Recent
Developments
COVID-19
As
of the time of this prospectus supplement, the impacts of the COVID-19 pandemic have been broad reaching, including impacts to
our retail and wholesale businesses. We temporarily closed our bricks and mortar stores for eight weeks across March to May 2020,
although we were able to continue to sell merchandise through our two online stores and fulfil online orders from the New Zealand
and U.S. warehouses. To mitigate the significant impact on cashflow we worked with suppliers to get support with delayed payments
and reached agreements with certain key suppliers to push back payments. In addition, we continue to negotiate support from landlords
to provide rent abatements through the period of closure and until revenue levels return to previous levels. Employees agreed
to work reduced hours and we have applied for government wage subsidies from the New Zealand and Australian governments. At the
date of this prospectus supplement, we have received NZ$2.0 million in subsidies from the New Zealand government and AU$0.5
million in subsidies from the Australian government. We have also been in discussion with the Bank of New Zealand (“BNZ”)
to defer loan repayments (see “Senior Secured Credit Facility” below). We are investigating other government
funding packages for which we may be eligible. The impact of COVID-19 in Asia delayed stock flow due to temporary factory closures.
We are working with suppliers who are now back operating to prioritize and reschedule orders and inventory flow has resumed.
As of the date of this prospectus, due
to a state of emergency being declared, the Australian stores in the state of Victoria have been closed temporarily from
August 3, 2020 and the Auckland stores in New Zealand are trading again after being closed for two weeks.
The
full impact of the COVID-19 pandemic continues to evolve, and, as such, it is uncertain as to the full magnitude that the pandemic
will have on our financial condition, liquidity, and future results of operations. Management and the directors are monitoring
the situation on a daily basis and forward planning to minimize the total impact to the group. For more information, see Item
5 of our Annual Report.
Senior
Secured Credit Facility
Effective
March 12, 2020, we entered into a Deed of Amendment and Restatement (the “Restated Facility Agreement”) that amended
and restated that certain Facility Agreement, originally dated June 27, 2016, as amended from time to time, by and among Bendon,
as borrower, us and certain subsidiaries and affiliates of ours, as guarantors, and BNZ, as lender. Under the Restated Facility
Agreement, BNZ will continue to make available (i) a revolving credit facility (the “Revolving Facility”), for which
the facility limit, as amended, currently is NZ$16.7 million, and (ii) an instrument facility (the “Instrument Facility”),
for which the facility limit is NZ$1.345 million. The Revolving Facility presently has an outstanding principal balance of NZ$16.7
million. We will reduce our indebtedness under the Restated Facility Agreement by an aggregate of NZ$7 million in periodic installments
through November 30, 2021, which will also reduce the facility limit under the Revolving Facility. The facilities terminate on
March 12, 2022. As at January 31, 2020, we were compliant under the facility covenants then in effect. However, we have not been
compliant with the financial covenants under the Restated Facility Agreement, due to the impact of COVID-19, and we are currently
in negotiations with BNZ to revise these temporarily. For more information, see Item 5.B of our Annual Report.
Convertible
Promissory Notes
Notes
Issued in October, November, and December 2019 and January, February, and April 2020
In
each of October, November and December 2019 and January, February, and April 2020, we completed a private placement of a convertible
promissory note (each, a “Note”) and a warrant to purchase Ordinary Shares to either St. George Investments LLC or
Iliad Research and Trading L.P., which are affiliates of one another (together, the “Affiliated Holders”). Each private
placement of a Note was made pursuant to a Securities Purchase Agreement with the applicable Affiliated Holder. The aggregate
purchase price of the Notes was US$15,500,000 (NZ$23,485,000). Each of the Notes was issued with an original issue discount of
5%, and certain expenses of the Affiliated Holder were added to the balance of each Note. In addition, the applicable Affiliated
Holder had the right to exchange each warrant for a 5% increase in the outstanding balance of the related Note, a right the Affiliated
Holder exercised in each case. Because we did not timely complete an equity financing as required by each of the Notes and did
not timely file a registration statement as required by the Notes issued in February and April 2020, the outstanding balance of
each applicable Note was increased by 10% for each such occurrence.
Each
of the Notes issued in October, November and December 2019 and January 2020 had an initial fixed conversion price of US$5.00 per
share (in the case of the October 2019 note) or US$4.00 per share (in the case of the other notes). Pursuant to amendments in
January 2020, on three occasions, we temporarily reduced the conversion price of the Note issued in December 2019. Furthermore,
pursuant to amendments in April and June 2020, we modified the Notes issued in October, November and December 2019 and January
2020 so that they could be converted at a floating conversion price, provided we approved each such conversion. Subject to our
approval, the holders of such Notes could convert the outstanding balance of the notes into Ordinary Shares at a conversion price
per share that was equal to (i) a percentage of not less than 75%, multiplied by (ii) the lowest daily volume weighted average
price of the Ordinary Shares in the preceding 20 trading days, but in any event not less than a specified floor price. As of September
24, 2020, the entire outstanding balance of the Notes issued in October, November and December 2019 and January 2020, or approximately
US$15,500,000 (NZ$23,700,000), had been converted into 35,746,486 Ordinary Shares.
In August 2020, we entered into a similar
amendment with respect the Note issued in February 2020, so that it also may be converted at a floating conversion price, provided
we approve each such conversion, on the same terms as described above. The Note issued in April 2020 remains convertible
only at its initial fixed conversion price. As of September 24, 2020, US$350,000 (NZ$530,000) of the Note issued in February
2020 had been converted into 1,875,670 Ordinary Shares.
Each of the remaining Notes issued in February
and April 2020 bears interest at 20% per annum, compounded daily, and matures two years after its issuance. As of September
24, 2020, the aggregate outstanding principal balance of the remaining Notes was approximately US$6,400,000 (NZ$9,700,000).
Note and Purchase Warrant Issued in July
2020
In July 2020, we completed a private placement
of a convertible promissory note (the “July Note”) and a warrant to purchase Ordinary Shares (the “July Purchase
Warrant”) to one of the Affiliated Holders, Iliad Research Trading L.P., pursuant to a Securities Purchase Agreement, for
an aggregate purchase price of US$8,000,000 (NZ$12,100,000). The July Note was issued with an original issue discount of 5%, and
certain expenses of the Affiliated Holder were added to the balance of the July Note, for an original principal balance of
US$8,420,000. We also granted a financing rebate to the Affiliated Holder, resulting in net proceeds to us of approximately
US$7,200,000 (NZ$10,900,000) from the sale of the July Note. The July Note accrues interest at the following rate: (i) for a period
of 90 days starting on its issuance date, 2.0% per annum, (ii) for the next 90 days, 10.0% per annum and (iii) thereafter, 15.0%
per annum. The July Note matures on the second anniversary of its issuance.
The July Note is convertible at the election
of the Affiliated Holder into Ordinary Shares at a conversion price equal to the lower of US$0.2424 (80% of the closing
bid price of the Ordinary Shares on the trading day immediately prior to August 24, 2020, the date the resale registration
statement for the Ordinary Shares underlying the July Note was declared effective). In addition, during the ten-day
period following August 24, 2020, we had the right to require the Affiliated Holder to convert the entire principal
amount of the July Note in excess of US$2,100,000, and all accrued interest on the July Note, into Ordinary Shares. Between
August 25 and September 2, 2020, the Affiliated Holder exercised its right to convert US$1,780,960 in principal amount of the
July Note, resulting in the issuance of 7,347,195 Ordinary Shares. On September 3, 2020, we exercised our right in full to require
conversion of the July Note. To the extent the Affiliated Holder would have beneficially owned more than 9.9%
of our outstanding Ordinary Shares after such required conversion, we issued to the Affiliated Holder “pre-funded”
warrants (the “July Pre-Funded Warrants”) in lieu of such shares. As a result, we issued 3,316,521 Ordinary Shares
and a July Pre-Funded Warrant to purchase 15,492,344 Ordinary Shares to the Affiliated Holder on September 3, 2020. As of September
24, 2020, the Affiliated Holder had exercised the July Pre-Funded Warrant in full. As of such date, the outstanding balance of
the July Note was approximately US$2,100,000 (NZ$3,200,000).
The July Purchase Warrant entitles the Affiliated
Holder to purchase Ordinary Shares at an exercise price of US$0.6707 per share. In addition, if the exercise price of the
July Purchase Warrants is higher than the last closing bid price of the Ordinary Shares, the July Purchase Warrants may be exercised
on a cashless basis for a number of shares equal to the Black-Scholes value per share underlying the July Purchase Warrant, multiplied
by the number of shares as to which the July Purchase Warrant is being exercised, divided by the closing bid price as of two business
days prior to the exercise date, but in any event not less than the Floor Price. For this purpose, the Black-Scholes value per
share underlying the July Purchase Warrant is a fixed value as set forth in the July Purchase Warrant. The July Purchase Warrant
expires on July 24, 2025. As of September 24, 2020, the July Purchase Warrant had been exercised as to 2,226,158 Ordinary Shares
on a cashless exercise using the Black-Scholes value, resulting in the issuance of 9,050,000 Ordinary Shares, and 16,910,206 Ordinary
Shares remain subject to the July Purchase Warrant.
ATM
Pursuant to the Sales Agreement and the
earlier prospectus supplement dated August 20, 2020, through September 24, 2020, we have sold an aggregate of 23,296,919 Ordinary
Shares for gross proceeds of US$3,617,219 and net proceeds of US$3,508,702, after payment to Maxim of an aggregate of US$108,517
in commissions.
Nasdaq
Noncompliance
On
March 11, 2020, we received a notice from the Nasdaq Listing Qualifications Department stating that, for the previous 30 consecutive
business days, the closing bid price for the Ordinary Shares had been below the minimum of US$1.00 per share required for continued
listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification letter stated that we would be afforded
180 calendar days to regain compliance with the minimum bid price requirement. In addition, Nasdaq has tolled the compliance period
from April 16, 2020 through June 30, 2020, due to the impact of COVID-19. Accordingly, we have until November 23, 2020 to regain
compliance with the minimum bid price requirement. In order to regain compliance, the closing bid price for the Ordinary Shares
must be at least US$1.00 per share for a minimum of ten consecutive business days. The notification letter also stated that in
the event we do not regain compliance within the 180-day period, we may be eligible for additional time.
On
May 14, 2020, we received a notice from the Nasdaq Listing Qualifications Department stating that we were no longer in compliance
with the equity standard for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies
to maintain stockholders’ equity of at least US$2,500,000 under the equity standard. Because our Annual Report reflected
stockholders’ equity of less than this amount, and we did not meet the alternative standards for market value of listed
securities or net income, we were no longer in compliance with Nasdaq’s continued listing standards. We submitted a plan
to regain compliance with this standard. On July 2, 2020, we received a letter from the Nasdaq staff stating that the staff had
determined to grant us an extension to regain compliance with Nasdaq’s equity standard for continued listing on Nasdaq.
Based on the plan of compliance submitted by us, of which this offering is a part, we have until November 10, 2020 to evidence
compliance with the equity standard.
The
Nasdaq notifications have no effect at this time on the listing of the Ordinary Shares, and the Ordinary Shares continue to trade
under the symbol “NAKD.”
Corporate
Information
Our
principal office is located at 8 Airpark Drive, Airport Oaks, Auckland 2022, New, Zealand, and our telephone number is +64 9 275
0000. Our registered office is located at 1/23 Court Road, Double Bay, New South Wales 2028, Australia. Our agent for service
of process in the United States is Graubard Miller, our U.S. counsel, located at The Chrysler Building, 405 Lexington Avenue,
New York, New York 10174. Our corporate website is located at www.nakedbrands.com. The information on our website shall
not be deemed part of this prospectus supplement.
Emerging
Growth Company
We
are an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”).
As an emerging growth company, we are eligible, and have elected, to take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies. These include, but are not
limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of
2002 and reduced disclosure obligations regarding executive compensation (to the extent applicable to a foreign private issuer).
We
could remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the consummation
of our initial public offering. However, if our annual gross revenue is US$1.07 billion or more, or our non-convertible debt issued
within a three year period exceeds US$1 billion, or the market value of our Ordinary Shares that are held by non-affiliates exceeds
US$700 million on the last day of the second fiscal quarter of any given fiscal year, we would cease to be an emerging growth
company as of the last day of that fiscal year.
Foreign
Private Issuer
We
are a “foreign private issuer” as defined under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). As a foreign private issuer under the Exchange Act, we are exempt from certain rules under the Exchange Act, including
the proxy rules, which impose certain disclosure and procedural requirements for proxy solicitations. Moreover, we are not required
to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic U.S. companies with securities
registered under the Exchange Act, and we are not required to comply with Regulation FD, which imposes certain restrictions on
the selective disclosure of material information. In addition, our officers, directors, and principal shareholders will be exempt
from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and the rules under
the Exchange Act with respect to their purchases and sales of our Ordinary Shares.
The
Nasdaq Listing Rules allow foreign private issuers, such as us, to follow home country corporate governance practices (in our
case Australian) in lieu of the otherwise applicable Nasdaq corporate governance requirements. In accordance with this exception,
we follow Australian corporate governance practices in lieu of certain of the Nasdaq corporate governance standards, as more fully
described in our Annual Report on Form 20-F for the fiscal year ended January 31, 2019, as amended, which is incorporated herein
by reference. See “Where You Can Find Additional Information” on page S-14.
Risks
Affecting Our Company
In
evaluating an investment in our securities, you should carefully read this prospectus supplement and especially consider the factors
incorporated by reference in the sections titled “Risk Factors” commencing on page S-7 of this prospectus supplement
and in our base prospectus and the Annual Report incorporated by reference herein.
THE
OFFERING
Issuer
|
Naked
Brand Group Ltd.
|
|
|
Securities
Offered
|
Ordinary
Shares having aggregate gross sales proceeds of up to US$18,500,000.
|
|
|
Ordinary
Shares to Be Outstanding Immediately Following This Offering
|
Up to 226,031,818 Ordinary Shares, assuming sales
of 124,023,175 Ordinary Shares in this offering at a price of US$0.12 per share, which was the last reported sale price of
our Ordinary Shares on Nasdaq as of September 24, 2020 (representing, in the aggregate, the remaining offering amount under
the Sales Agreement as of such date). The actual number of Ordinary Shares will vary depending on the sales price under
this offering.(1)
|
|
|
Manner
of Offering
|
We have entered into a Sales Agreement with Maxim
relating to the sale of our Ordinary Shares. In accordance with the terms of the Sales Agreement, under this prospectus supplement
we may offer and sell, from time to time, Ordinary Shares having an aggregate offering price of up to US$18,500,000
through Maxim acting as our exclusive sales agent. Sales of Ordinary Shares, if any, under this prospectus supplement will
be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415 under the Securities
Act. If we are eligible and desire to offer additional Ordinary Shares pursuant to the Sales Agreement, we will file an additional
prospectus supplement to register such additional Ordinary Shares. See the section titled “Plan of Distribution”
on page S-13 of this prospectus supplement.
|
|
|
Use
of Proceeds
|
We
may issue and sell our Ordinary Shares having an aggregate offering price of up to $18,500,000 from time to time under
this prospectus supplement and the accompanying prospectus. Because there is no minimum offering amount required as a condition
to close this offering, the actual public offering amount, commissions to Maxim and proceeds to us, if any, are not determinable
at this time. There can be no assurance that we will sell any Ordinary Shares, under the Sales Agreement. We intend to use
the net proceeds from the sale of the securities offered hereby for working capital and other general corporate purposes.
See the section titled “Use of Proceeds” on page S-10.
|
|
|
Risk
Factors
|
See
the sections titled “Risk Factors” commencing on page S-7 of this prospectus supplement and in our base
prospectus and the Annual Report incorporated by reference herein for a discussion of factors you should consider carefully
before deciding to invest in our Ordinary Shares.
|
|
|
Listing
|
Our
Ordinary Shares are listed on the Nasdaq Capital Market under the symbol “NAKD”.
|
|
|
Transfer
Agent
|
Continental
Stock Transfer & Trust Co. is the registrar and transfer agent of our Ordinary Shares.
|
(1)
|
The number of Ordinary
Shares to be issued and outstanding after this offering is based on 96,309,695 Ordinary Shares issued and outstanding as of
September 24, 2020 and 5,698,948 Ordinary Shares sold under the Sales Agreement through September 24, 2020 but not
yet issued. The number of Ordinary Shares to be issued and outstanding after this offering excludes:
|
|
●
|
8,672,992 Ordinary
Shares estimated to be issuable upon conversion of the July Note (assuming that the balance of the note and all accrued interest
thereon as of September 24, 2020 was converted in full at the current conversion price) and 16,910,206 Ordinary
Shares underlying the July Purchase Warrant. However, the actual number of shares issuable upon exercise of the July Purchase
Warrant may be substantially more than the foregoing amount, depending, among other things, on whether the July Purchase Warrant
is exercised through a Black-Scholes cashless exercise. In such event, the number of shares issuable upon exercise of the
July Purchase Warrant would depend on the market price of the Ordinary Shares at a future date. We cannot predict the market
price of our Ordinary Shares at any future date, and therefore, we are unable to accurately forecast or predict the total
amount of shares that ultimately may be issued;
|
|
|
|
|
●
|
1,603,393 Ordinary Shares estimated to be issuable upon
the conversion of the Notes issued in February and April 2020 (assuming that the balance of each such note as of September
24, 2020 was converted in full at the fixed conversion price provided in each such note). However, the actual number of shares
issuable upon conversion of such Notes may be substantially more than the foregoing amount, because the Note issued in February
2020 may be converted at a floating conversion price based on the current market price of our Ordinary Shares, provided we approve
such conversion. Subject to our approval, the holder of such Note may convert the outstanding balance of such notes into the Ordinary
Shares at a floating conversion price per share that is equal to (i) a percentage of not less than 75%, multiplied by (ii) the
lowest daily volume weighted average price of the Ordinary Shares in the preceding 20 trading days, but in any event not less
than a specified floor price. Based on the outstanding balance of approximately US$4,206,300 as of September 24,
2020, and an assumed floating conversion price of US$0.15 (which is the floor price), the Note issued in February
2020 would be convertible into approximately 28,042,180 Ordinary Shares. We cannot predict the market price of our Ordinary
Shares at any future date, and therefore, we are unable to accurately forecast or predict the total amount of shares that ultimately
may be issued under the Note issued in February 2020; and
|
|
|
|
|
●
|
592,900 Ordinary Shares underlying our other outstanding warrants.
|
RISK
FACTORS
An
investment in our securities involves a high degree of risk. Before investing in our Ordinary Shares, you should carefully consider
the risk factors set forth below and those described under “Risk Factors” in the documents incorporated by reference
herein, including in our most recent Annual Report on Form 20-F filed with the SEC, together with the other information included
in this prospectus and incorporated by reference herein from our filings with the SEC. If any of such risks or uncertainties occurs,
our business, financial condition, and operating results could be materially and adversely affected. Additional risks and uncertainties
not currently known to us or that we currently deem immaterial also may materially and adversely affect our business operations.
As a result, the trading price of our Ordinary Shares could decline and you could lose all or a part of your investment.
Risks
Relating to Our Business
Our
business, results of operations, and financial condition may be impacted by the recent coronavirus (COVID-19) outbreak.
Our
business has been and may continue to be adversely affected by a widespread outbreak of contagious disease, including the recent
COVID-19 pandemic, resulting in business closures and a limit on consumer and employee travel across the globe. Any outbreak of
contagious diseases, or other adverse public health developments, could have a material and adverse effect on our business operations.
These could include disruptions or restrictions on our ability to travel, reduced traffic in our stores and the stores of our
wholesale customers, temporary closures of our stores and/or office buildings or the facilities of our wholesale customers or
suppliers. We may also see disruptions or delays in shipments and negative impacts to pricing of certain components of our products.
Further, any disruption of our customers or suppliers would likely impact our sales and operating results. In addition, a significant
outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect
the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for our products
and likely impact our operating results. The resulting economic downturn can also negatively impact our share price.
As
of the time of this filing, the impacts of the COVID-19 pandemic have been broad reaching, including impacts to our retail and
wholesale businesses. The pandemic has had an impact on our business globally, with significant temporary store closures. The
COVID-19 pandemic is also impacting the Asia region where we source most of our inventory. Temporary factory closures and the
pace of workers returning to work has impacted our suppliers’ ability to source certain raw materials and to produce and
fulfill finished goods orders in a timely manner. As of the date of this filing, we have also experienced impacts on deliveries,
driven primarily by factory labor shortages and port congestion. However, the ability of our distribution and logistics providers
to operate may be further impacted depending on the continued severity and duration of the pandemic and may have a significant
impact on the cost and timing of receipts for future seasons. The occurrence of any of these events could further negatively impact
our future consolidated financial position, results of operations and cash flows. There could be a prolonged impact on our business
due to slow economic recovery or changes in consumer behavior. If we experience a sustained decrease in consumer demand related
to the COVID-19 pandemic, it may exacerbate our need for additional financing. There is no guarantee that we will be able to obtain
such additional financing, on acceptable terms or at all. The results for the first quarter of fiscal 2021 as well as full fiscal
2021 could also be impacted in ways we are not able to predict today, including, but not limited to, non-cash write-downs and
asset impairment charges (including impairments on property and equipment, operating lease right-of use assets and goodwill);
unrealized gains or losses related to investments; foreign currency fluctuations; and collections of accounts receivables.
We are continuing to monitor the potential
impact of the COVID-19 pandemic. As of the date of this prospectus, the Australian stores in the state of Victoria remain
temporarily closed since August 3, 2020 and the Auckland stores in New Zealand are trading again following a two
week closure due to a state of emergency being declared.
The
two online stores are trading, and we are able to fulfil orders from the New Zealand and U.S. warehouses. In order to mitigate
the significant impact on cash inflow we are working with our suppliers and lenders to extend payment terms. We are in discussions
with BNZ to extend loan repayment dates and with our landlords to provide abatements through the period of closure. We have reduced
staff hours and applied for government subsidies for the New Zealand and Australian employees. At the date of this prospectus,
we had received NZ$2.0m in subsidies from the New Zealand government and AU$0.5m from the Australian government.
We
are and may become the subject of various claims, threats of litigation, litigation or investigations which could have a material
adverse effect on our business, financial condition, results of operations or price of our ordinary shares.
We
are and may become subject to various claims, threats of litigation (including, from current and former shareholders of our company),
litigation or investigations, including commercial disputes and employee claims, and from time to time may be involved in governmental
or regulatory investigations or similar matters. Any claims asserted against us or our management, regardless of merit or eventual
outcome, could harm our reputation and have an adverse impact on our relationship with our clients, distribution partners and
other third parties and could lead to additional related claims. Furthermore, there is no guarantee that we will be successful
in defending ourselves in pending or future litigation or similar matters under various laws. Any judgments or settlements in
any pending litigation or future claims, litigation or investigation could have a material adverse effect on our business, financial
condition, results of operations and price of our Ordinary Shares.
Risks
Related to this Offering
It
is not possible to predict the actual number of Ordinary Shares we will sell under the Sales Agreement, or the gross proceeds
resulting from those sales.
Subject
to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement
notice to Maxim at any time throughout the term of the Sales Agreement. The number of Ordinary Shares that are sold through Maxim
will fluctuate based on a number of factors, including the market price of the Ordinary Shares during the sales period, the limits
we set with Maxim in any applicable placement notice, and the demand for our Ordinary Shares during the sales period. Because
the price per share of each share sold will fluctuate during the sales period, it is not possible to predict the number of shares
that will be sold or the gross proceeds we will raise in connection with those sales.
The
Ordinary Shares offered hereby will be sold in “at the market offerings” and investors who buy shares at different
times will likely pay different prices.
Investors
who purchase Ordinary Shares in this offering at different times will likely pay different prices, and so may experience different
levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary
the timing, prices, and numbers of shares sold in this offering. In addition, there is no minimum or maximum sales price of our
Ordinary Shares offered hereby. Investors may experience a decline in the value of shares that they purchase in this offering
as a result of sales made at prices lower than the prices they paid.
You
may experience immediate dilution in the net tangible book value per Ordinary Share that you purchase.
The price per Ordinary Share offered hereunder
may be higher than the net tangible book value per Ordinary Share prior to your purchase. In such event, you will suffer
immediate dilution in an amount representing the difference between our net tangible book value per Ordinary Share
after giving effect to your purchase and the purchase price per Ordinary Share that you pay in the offering.
We
will have broad discretion in using the proceeds of this offering, and we may not effectively spend the proceeds.
We
will use the net proceeds of this offering for working capital and general corporate purposes. We have not allocated any specific
portion of the net proceeds to any particular purpose, and our management will have the discretion to allocate the proceeds as
it determines. We will have significant flexibility and broad discretion in applying the net proceeds of this offering, and we
may not apply these proceeds effectively. Our management might not be able to yield a significant return, if any, on any investment
of these net proceeds, and you will not have the opportunity to influence our decisions on how to use our net proceeds from this
offering.
Risks
Related to our Ordinary Shares
We
may issue additional securities in the future, which may result in dilution to our shareholders.
We
are not restricted from issuing additional Ordinary Shares or securities convertible into or exchangeable for Ordinary Shares.
Because we anticipate we will need to raise additional capital to operate and/or expand our business, we expect to conduct additional
equity offerings in future.
We also may issue additional Ordinary Shares
upon conversion of our outstanding convertible promissory notes and upon exercise of our outstanding warrants. As of September
24, 2020, there were 8,672,992 Ordinary Shares estimated to be issuable upon conversion of the July Note (assuming
that the balance of the note and all accrued interest thereon as of such date was converted in full at the current conversion
price) and 16,910,206 Ordinary Shares underlying the July Purchase Warrant. However, the actual number of shares issuable
upon exercise of the July Purchase Warrant may be substantially more than the foregoing amount, depending, among other things,
on whether the July Purchase Warrant is exercised through a Black-Scholes cashless exercise. In such event, the number of shares
issuable upon exercise of the July Purchase Warrant would depend on the market price of the Ordinary Shares at a future date.
We cannot predict the market price of our Ordinary Shares at any future date, and therefore, we are unable to accurately forecast
or predict the total amount of shares that ultimately may be issued.
In addition, as of September 24, 2020,
there were 1,603,393 Ordinary Shares estimated to be issuable upon the conversion of the Notes issued in February and
April 2020 (assuming that the balance of each such note as of such date was converted in full at the fixed conversion price provided
in each such note) and 592,900 Ordinary Shares underlying our other outstanding warrants. However, the actual number of shares
issuable upon conversion of the Notes issued in February and April 2020 may be substantially more than the foregoing amount, because
the Note issued in February 2020 may be converted at a floating conversion price based on the current market price of our Ordinary
Shares, provided we approve such conversion. Subject to our approval, the holder of such Note may convert the outstanding balance
of such notes into the Ordinary Shares at a floating conversion price per share that is equal to (i) a percentage of not less
than 75%, multiplied by (ii) the lowest daily volume weighted average price of the Ordinary Shares in the preceding 20 trading
days, but in any event not less than a specified floor price. Based on the outstanding balance of approximately US$4,206,300
as of September 24, 2020, and an assumed floating conversion price of US$0.15 (which is the floor price),
the Note issued in February 2020 would be convertible into approximately 28,042,180 Ordinary Shares. We cannot predict
the market price of our Ordinary Shares at any future date, and therefore, we are unable to accurately forecast or predict the
total amount of shares that ultimately may be issued under the Note issued in February 2020.
There is no limit on the number of Ordinary Shares we may issue
under our constitution. To the extent our outstanding warrants are exercised, our outstanding convertible promissory notes are
converted or we conduct additional equity offerings, additional Ordinary Shares will be issued, which may result in dilution to
our shareholders. Sales of substantial numbers of shares in the public market could adversely affect the market price of our Ordinary
Shares. In addition, issuances of a substantial number of shares will reduce the equity interest of our existing investors and
could cause a change in control of our company.
Nasdaq
may delist our Ordinary Shares from quotation on its exchange, which could limit investors’ ability to sell and purchase
our securities and subject us to additional trading restrictions.
The
Ordinary Shares are currently listed on Nasdaq under the trading symbol “NAKD”. However, on March 11, 2020, we received
a notice from the Nasdaq Listing Qualifications Department stating that, for the previous 30 consecutive business days, the closing
bid price for the Ordinary Shares had been below the minimum of US$1.00 per share required for continued inclusion on the Nasdaq
Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification letter stated that we would be afforded 180 calendar days
to regain compliance with the minimum bid price requirement. In addition, Nasdaq has tolled the compliance period from April 16,
2020 through June 30, 2020, due to the impact of COVID-19. Accordingly, we have until November 23, 2020 to regain compliance with
the minimum bid price requirement. In order to regain compliance, the closing bid price for the Ordinary Shares must be at least
US$1.00 per share for a minimum of ten consecutive business days. The notification letter also stated that in the event we do
not regain compliance within the 180-day period, we may be eligible for additional time.
In
addition, on May 14, 2020, we received a notice from the Nasdaq Listing Qualifications Department stating that we were no longer
in compliance with the equity standard for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires
listed companies to maintain stockholders’ equity of at least US$2,500,000 under the equity standard. Because our Annual
Report reflected stockholders’ equity of less than this amount, and we did not meet the alternative standards for market
value of listed securities or net income, we were no longer in compliance with Nasdaq’s continued listing standards. We
submitted a plan to regain compliance with this standard. On July 2, 2020, we received a letter from the Nasdaq staff stating
that the staff had determined to grant us an extension to regain compliance with Nasdaq’s equity standard for continued
listing on Nasdaq. Based on the plan of compliance submitted by us, of which the offering of the July Note and July Purchase Warrant
and this offering are a part, we have until November 10, 2020 to evidence compliance with the equity standard.
There
can be no assurance that we will regain compliance with the minimum bid price requirement or the equity standard within the allotted
period, or that we will be able to maintain compliance with the other continued listing requirements under the Nasdaq Listing
Rules.
If
the Ordinary Shares are not listed on Nasdaq at any time after this offering, we could face significant material adverse consequences,
including:
|
●
|
a
limited availability of market quotations for our securities;
|
|
|
|
|
●
|
reduced
liquidity;
|
|
|
|
|
●
|
a
determination that the Ordinary Shares are a “penny stock” which will require brokers trading in our shares to
adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market
for the Ordinary Shares;
|
|
|
|
|
●
|
a
limited amount of news and analyst coverage for our company; and
|
|
|
|
|
●
|
a
decreased ability to issue additional securities or obtain additional financing in the future.
|
The
market for our Ordinary Shares may not provide investors with adequate liquidity.
Liquidity
of the market for our Ordinary Shares depends on a number of factors, including our financial condition and operating results,
the number of holders of our Ordinary Shares, the market for similar securities and the interest of securities dealers in making
a market in the securities. We cannot predict the extent to which investor interest in the Company will maintain a trading market
in our Ordinary Shares, or how liquid that market will be. If an active market is not maintained, investors may have difficulty
selling Ordinary Shares that they hold.
We
do not intend to pay any dividends on our Ordinary Shares at this time.
We
have not paid any cash dividends on our Ordinary Shares to date. The payment of cash dividends on our Ordinary Shares in the future
will be dependent upon our revenue and earnings, if any, capital requirements, and general financial condition, as well as the
limitations on dividends and distributions that exist under the laws and regulations of Australia, and will be within the discretion
of our board of directors. It is the present intention of our board of directors to retain all earnings, if any, for use in our
business operations and, accordingly, our board of directors does not anticipate declaring any dividends on our Ordinary Shares
in the foreseeable future. As a result, any gain you will realize on our Ordinary Shares will result solely from the appreciation
of such shares.
USE
OF PROCEEDS
We
may issue and sell our Ordinary Shares having an aggregate offering price of up to $18,500,000 from time to time under
this prospectus supplement and the accompanying prospectus. Because there is no minimum offering amount required as a condition
to close this offering, the actual public offering amount, commissions to Maxim and proceeds to us, if any, are not determinable
at this time. There can be no assurance that we will sell any Ordinary Shares, under the Sales Agreement.
We
intend to use the net proceeds from the sale of the securities offered hereby for working capital and other general corporate
purposes.
The
expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions,
which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures
may vary significantly depending on numerous factors, including but not limited to the impact of the COVID-19 pandemic on our
business operations and any unforeseen cash needs. As a result, our management retains broad discretion over the allocation of
the net proceeds from this offering.
CAPITALIZATION
The following table sets forth our capitalization
as of January 31, 2020 on (i) a historical basis, (ii) on a pro forma basis, after giving effect to the transactions described
in footnote 1 to the table (the “Subsequent Transactions”), and (iii) on a pro forma as adjusted basis, after giving
further effect to the sale by us of an aggregate of 124,023,175 Ordinary Shares offered hereby at an assumed offering price of
US$0.12 per share, which was the closing sale price of our Ordinary Shares on Nasdaq on September 24, 2020 (representing, in the
aggregate, the remaining offering amount under the Sales Agreement as of such date), after deducting estimated offering
expenses payable by us.
You
should read this table together with our financial statements and the related notes thereto, as well as “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and the other financial information, incorporated
by reference in this prospectus supplement or the accompanying base prospectus from our SEC filings, including our Annual Report.
In
Thousands of NZ$ and US$
|
|
As
at January 31, 2020
(Historical)
|
|
|
As
at January 31, 2020
(Pro
Forma) (1)
|
|
|
As
at January 31, 2020
(Pro
Forma As Adjusted)(2)
|
|
|
|
NZ$
|
|
|
US$
(3)
|
|
|
NZ$
|
|
|
US$
(3)
|
|
|
NZ$
|
|
|
US$(3)
|
|
Borrowings
|
|
|
38,913
|
|
|
|
25,683
|
|
|
|
27,719
|
|
|
|
18,295
|
|
|
|
27,7019
|
|
|
|
18,295
|
|
Share
Capital
|
|
|
170,913
|
|
|
|
112,327
|
|
|
|
209,883
|
|
|
|
138,523
|
|
|
|
232,432
|
|
|
|
153,405
|
|
Accumulated
Losses
|
|
|
(176,595
|
)
|
|
|
(116,553
|
)
|
|
|
(176,595
|
)
|
|
|
(116,553
|
)
|
|
|
(176,595
|
)
|
|
|
(116,553
|
)
|
Reserves
|
|
|
118
|
|
|
|
78
|
|
|
|
118
|
|
|
|
78
|
|
|
|
118
|
|
|
|
78
|
|
Total
Capitalization
|
|
|
(6,284
|
)
|
|
|
(4,147
|
)
|
|
|
33,406
|
|
|
|
22,048
|
|
|
|
55,955
|
|
|
|
36,931
|
|
(1)
|
The
pro forma information gives effect to the following transactions:
|
|
●
|
On
February 12, 2020, we completed a private placement of a Note and a warrant to purchase Ordinary Shares, for a purchase price
of US$3.0 million, with a principal balance before discount and expenses of US$3.17 million (NZ$4.8 million). The holder exercised
the right to exchange the warrant for a 5% increase in the balance of the Note, and as a result the warrant was cancelled,
and the balance of the Note was increased by approximately US$0.2 million (NZ$0.2 million). We also did not timely complete
an equity financing and did not timely file a registration statement as required by the Note, and as a result the outstanding
balance of the Note was subjected to a 10% premium for each such occurrence, or an aggregate of approximately US$0.7 million
(NZ$1.1 million). The Note accrues interest at a rate of 20% per annum, compounded daily.
|
|
|
|
|
●
|
On
April 15, 2020, we completed a private placement of a Note and a warrant to purchase Ordinary Shares, for a purchase price
of US$1.5 million, with a principal balance before discount and expenses of US$1.595 million (NZ$2.4 million). The holder
exercised the right to exchange the warrant for a 5% increase in the balance of the Note, and as a result the warrant was
cancelled, and the balance of the Note was increased by approximately US$0.1 million (NZ$0.1 million). We also did not timely
complete an equity financing and did not timely file a registration statement as required by the Note, and as a result the
outstanding balance of the Note was subjected to a 10% premium for each such occurrence, or an aggregate of approximately
US$0.4 million (NZ$0.55 million). The Note accrues interest at a rate of 20% per annum, compounded daily.
|
|
|
|
|
●
|
On
July 3, 2020, we agreed to exchange one of our outstanding promissory notes, with an outstanding balance of approximately
US$1.36 million (NZ$2.1 million), for 1,666,667 of our Ordinary Shares.
|
|
|
|
|
●
|
From
February 1, 2020 through September 24, 2020, an aggregate of US$15.0 million (NZ$22.7 million) of the outstanding balance
of the Notes issued in October, November and December 2019 and January 2020, representing all of the outstanding balance
of such notes, and US$350,000 (NZ$530,000) of the outstanding balance of the Note issued in February 2020 was converted
into 37,622,156 Ordinary Shares.
|
|
|
|
|
●
|
On
July 24, 2020, we completed a private placement of the July Note and the July Purchase Warrant, for a purchase price
of US$8.0 million, with an original issue discount of 5%, certain expenses added to the principal balance, and a financing
rebate granted to the investor, resulting in net proceeds to us of approximately US$7,200,000 (NZ$10,900,000). The July
Note accrues interest at the following rate: (i) for a period of 90 days starting on its issuance date, 2.0% per annum, (ii)
for the next 90 days, 10.0% per annum and (iii) thereafter, 15.0% per annum. The July Note has a conversion price of US$0.2424
per share. Between August 25 and September 2, 2020, the Affiliated Holder exercised its right to convert US$1,780,960 in principal
amount of the July Note, resulting in the issuance of 7,347,195 Ordinary Shares. On September 3, 2020, we exercised our right
to require conversion of the principal amount of the July Note in excess of $2,100,000 and all accrued interest on the July
Note. To the extent the Affiliated Holder would have beneficially owned more than 9.9% of our outstanding Ordinary Shares
after such required conversion, we issued to the Affiliated Holder “pre-funded” warrants (the “July Pre-Funded
Warrants”) in lieu of such shares. As a result, we issued 3,316,521 Ordinary Shares and a July Pre-Funded Warrant to
purchase 15,492,344 Ordinary Shares to the Affiliated Holder on September 3, 2020. As of September 24, 2020, the Affiliated
Holder had exercised the July Pre-Funded Warrant in full. As of such date, the outstanding balance of the July Note was approximately
US$2,100,000 (NZ$3,200,000).
|
|
|
|
|
●
|
Through
September 24, 2020, we have sold an aggregate of 23,296,919 Ordinary Shares for gross
proceeds of US$3,617,219 and net proceeds of US$3,508,702, after payment to Maxim of
an aggregate of US$108,517 in commissions, pursuant to the Sales Agreement with Maxim.
|
(2)
|
The
pro forma as adjusted information gives further effect to the sale by us of an aggregate of 124,023,175 Ordinary Shares offered
hereby at an assumed offering price of US$0.12 per share, which was the closing sale price of our Ordinary Shares on Nasdaq
on September 24, 2020 (representing, in the aggregate, the remaining offering amount under the Sales Agreement as of such
date), after deducting estimated offering expenses payable by us.
|
|
|
(3)
|
In
this prospectus supplement certain New Zealand dollar amounts have been translated into United States dollars at the rate
as at January 31, 2020 of NZ$1 = US$0.66. Such translations should not be construed as representations that the New Zealand
dollar amounts represent, or have been or could be converted into, United States dollars at that or any other rate.
|
The
foregoing table does not take into account the conversion or exercise of the convertible securities and warrants set forth in
footnote 1 in “Prospectus Supplement Summary – The Offering.”
You
should read this table in conjunction with our consolidated financial statements as at and for the fiscal year ended January 31,
2020, which are incorporated by reference in this prospectus supplement.
DESCRIPTION
OF ORDINARY SHARES
For
a description of the rights associated with the Ordinary Shares, see “Description of Capital Shares” in the
accompanying base prospectus and the description of our Ordinary Shares included as Exhibit 2.2 to our Annual Report with the
SEC on May 8, 2020 and incorporated by reference herein.
Assuming
that an aggregate of 124,023,175 Ordinary Shares are sold in this offering at an assumed offering price of US$0.12 per share,
which was the closing sale price of our Ordinary Shares on Nasdaq on September 24, 2020 (representing, in the aggregate, the remaining
offering amount under the Sales Agreement as of such date), there will be 226,031,818 Ordinary Shares outstanding, which
does not include the Ordinary Shares issuable upon conversion of our outstanding convertible promissory notes and upon exercise
of our outstanding warrants. The number of Ordinary Shares to be issued and outstanding after this offering is based on 96,309,695
Ordinary Shares issued and outstanding as of September 24, 2020 and 5,698,948 Ordinary Shares sold under the Sales Agreement through
September 24, 2020 but not yet issued.
As
of September 24, 2020, there were 8,672,992 Ordinary Shares estimated to be issuable upon conversion of the July
Note (assuming that the balance of the note and all accrued interest thereon as of such date was converted in full at the current
conversion price) and 16,910,206 Ordinary Shares underlying the July Purchase Warrant. However, the actual number of shares
issuable upon exercise of the July Purchase Warrant may be substantially more than the foregoing amount, depending, among other
things, on whether the July Purchase Warrant is exercised through a Black-Scholes cashless exercise. In such event, the number
of shares issuable upon exercise of the July Purchase Warrant would depend on the market price of the Ordinary Shares at a future
date. We cannot predict the market price of our Ordinary Shares at any future date, and therefore, we are unable to accurately
forecast or predict the total amount of shares that ultimately may be issued.
In
addition, as of September 24, 2020, there were 1,603,393 Ordinary Shares estimated to be issuable upon the conversion
of the Notes issued in February and April 2020 (assuming that the balance of each such note as of such date was converted in full
at the fixed conversion price provided in each such note) and 592,900 Ordinary Shares underlying our other outstanding warrants.
However, the actual number of shares issuable upon conversion of the Notes issued in February and April 2020 may be substantially
more than the foregoing amount, because the Note issued in February 2020 may be converted at a floating conversion price based
on the current market price of our Ordinary Shares, provided we approve such conversion. Subject to our approval, the holder of
such Note may convert the outstanding balance of such notes into the Ordinary Shares at a floating conversion price per share
that is equal to (i) a percentage of not less than 75%, multiplied by (ii) the lowest daily volume weighted average price of the
Ordinary Shares in the preceding 20 trading days, but in any event not less than a specified floor price. Based on the outstanding
balance of approximately US$4,206,300 as of September 24, 2020, and an assumed floating conversion price of US$0.15
(which is the floor price), the Note issued in February 2020 would be convertible into approximately 28,042,180
Ordinary Shares. We cannot predict the market price of our Ordinary Shares at any future date, and therefore, we are unable
to accurately forecast or predict the total amount of shares that ultimately may be issued under the Note issued in February 2020.
CERTAIN
TAX CONSIDERATIONS
You
should carefully read the discussion of the material Australian and U.S. federal income tax considerations associated with our
operations and the acquisition, ownership and disposition of our Ordinary Shares set forth in Section E, “Taxation,”
of Item 10 of our Annual Report, filed with the SEC on May 8, 2020 and incorporated by reference herein.
PLAN
OF DISTRIBUTION
Pursuant
to the Sales Agreement, entered into by and between the Company and Maxim Group LLC (“Maxim”), Maxim has agreed to
act as exclusive sales agent in connection with this offering of our Ordinary Shares pursuant to this prospectus supplement and
the accompanying prospectus. Maxim is not purchasing or selling any of the Ordinary Shares offered by this prospectus supplement,
nor is it required to arrange the purchase or sale of any specific number or dollar amount of Ordinary Shares, but have agreed
to use their reasonable best efforts to arrange for the sale of all of the Ordinary Shares offered hereby.
Upon
delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Maxim may sell Ordinary Shares
by any method permitted by law deemed to be an “at-the-market” equity offering as defined in Rule 415 promulgated
under the Securities Act, including sales made directly on or through Nasdaq, the existing trading market for our Ordinary Shares,
sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing
at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law, including
in privately negotiated transactions.
We
will pay Maxim a commission of up to 3% of the gross proceeds from each sale. We also reimbursed Maxim US$45,000
for its costs and expenses relating to the Sales Agreement, including legal expenses and paid US$10,000 for background
checks of our directors and officers. In addition to such fees, in connection with periodic bringdowns of Maxim’s due
diligence and certain opinions, letters and certificates delivered under the Sales Agreement, we have agreed to pay Maxim’s
legal counsel up to an additional $5,000 per bringdown. Because there is no minimum offering amount required as a condition to
close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at
this time. We estimate that the total expenses for the offering, excluding compensation and reimbursements payable to Maxim under
the terms of the Sales Agreement, will be approximately US$98,000.
Settlement
for sales of Ordinary Shares will occur on the second business day following the date on which any sales are made, or on some
other date that is agreed upon by us and Maxim in connection with a particular transaction, in return for payment of the net proceeds
to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. Sales of Ordinary Shares as
contemplated in this prospectus supplement and the accompany prospectus will be settled through the facilities of The Depository
Trust Company or by such other means as we and Maxim may agree upon.
We
have agreed to provide indemnification and contribution to Maxim and specified persons against certain civil liabilities, including
liabilities under the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and to contribute
to payments that Maxim may be required to make in respect of such liabilities.
Maxim
may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received
by them and any profit realized on the resale of the shares sold by them while acting as principal might be deemed to be underwriting
discounts or commissions under the Securities Act. As an underwriter, Maxim would be required to comply with the requirements
of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5
and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares by
the agent acting as principal. Under these rules and regulations, Maxim:
|
●
|
may
not engage in any stabilization activity in connection with our securities; and
|
|
|
|
|
●
|
may
not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than
as permitted under the Exchange Act, until it has completed its participation in the distribution.
|
The
offering of our Ordinary Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all shares
of our Ordinary Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement as permitted therein. Either
we or the Sales Agent may terminate the Sales Agreement at any time upon ten (10) days’ prior notice.
Maxim
and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us
and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M,
Maxim will not engage in any market making activities involving our Ordinary Shares while the offering is ongoing under this prospectus
supplement and the accompany prospectus.
This
prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Maxim
and Maxim may distribute this prospectus supplement and the accompanying prospectus electronically.
The
foregoing does not purport to be a complete statement of the terms and conditions of the Sales Agreement. A copy of the Sales
Agreement is included as an exhibit to our Current Report on Form 8-K that will be filed with the SEC and incorporated by reference
into the registration statement of which this prospectus supplement and the accompanying prospectus form a part.
EXPENSES
The
following are the estimated expenses of the issuance and distribution of the securities offered by this prospectus supplement,
all of which will be paid by us.
In US$
|
|
|
|
Legal Fees and Expenses
|
|
$
|
65,000
|
|
Accountants’ Fees and Expenses
|
|
$
|
28,000
|
|
Miscellaneous Costs
|
|
$
|
5,000
|
|
Total
|
|
$
|
98,000
|
|
LEGAL
MATTERS
Graubard
Miller, New York, New York, is acting as counsel in connection with the registration of our securities under the Securities Act.
HWL Ebsworth Lawyers, Sydney, Australia, will pass upon the validity of the Ordinary Shares offered in this prospectus and on
matters of Australia law. Ellenoff Grossman & Schole LLP, New York, New York, is representing the sales agent in this offering.
EXPERTS
The
financial statements as of January 31, 2020 and 2019 and for each of the three years in the period ended January 31, 2020, incorporated
by reference in this prospectus supplement, have been so included in reliance on the report (which contains an explanatory paragraph
relating to our ability to continue as a going concern as described in Note 2 to the financial statements) of BDO Audit Pty Ltd,
an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.
SERVICE
OF PROCESS AND ENFORCEMENT OF CIVIL LIABILITIES
We
are an Australian company and our executive offices are located outside of the United States. Certain of our directors and officers
and some of the experts in this prospectus reside outside the United States. In addition, a substantial portion of our assets
and the assets of our directors, officers and experts are located outside of the United States. As a result, you may have difficulty
serving legal process within the United States upon us or any of these persons. You may also have difficulty enforcing, both in
and outside of the United States, judgments you may obtain in U.S. courts against us or these persons in any action, including
actions based upon the civil liability provisions of U.S. federal or state securities laws. Furthermore, there is substantial
doubt that the courts of Australia would enter judgments in original actions brought in those courts predicated on U.S. federal
or state securities laws.
WHERE
YOU CAN FIND ADDITIONAL INFORMATION
We
have filed with the SEC a registration statement on Form F-3 with respect to the Ordinary Shares offered hereby. This prospectus,
which forms a part of the registration statement, does not contain all of the information set forth in the registration statement
and the exhibits thereto. The registration statement includes and incorporates by reference additional information and exhibits.
Statements made in this prospectus concerning the contents of any contract, agreement or other document filed as an exhibit to
the registration statement are summaries of the material terms of such contracts, agreements or documents, but do not repeat all
of their terms. Reference is made to each such exhibit for a more complete description of the matters involved and such statements
shall be deemed qualified in their entirety by such reference. The registration statement and the exhibits and schedules thereto
filed with the SEC are available without charge on the website maintained by the SEC at http://www.sec.gov that contains periodic
reports and other information regarding registrants that file electronically with the SEC.
We
are subject to the information and periodic reporting requirements of the Exchange Act and we file periodic reports and other
information with the SEC. These periodic reports and other information are available on the website of the SEC referred to above.
As a “foreign private issuer,” we are exempt from the rules under the Exchange Act prescribing the furnishing and
content of proxy statements to shareholders. Those proxy statements are not expected to conform to Schedule 14A of the proxy rules
promulgated under the Exchange Act. In addition, as a “foreign private issuer,” we are exempt from the rules under
the Exchange Act relating to short swing profit reporting and liability.
INCORPORATION
BY REFERENCE OF CERTAIN DOCUMENTS
The
SEC allows us to incorporate by reference the information we file with it, which means that we can disclose important information
to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus.
This prospectus incorporates by reference our documents listed below:
|
●
|
our
Annual Report on Form 20-F filed with the SEC on May 8, 2020;
|
|
|
|
|
●
|
our
reports on Form 6-K filed with the SEC on February 6, 2020, February 13, 2020, March
11, 2020, March 12, 2020, April 16, 2020, April 30, 2020, May 15, 2020, June 10, 2020,
July 8, 2020, July 27, 2020 (as amended on August 10, 2020), July 31, 2020, August
19, 2020, August 20, 2020 (as amended on August 21, 2020) and August 31, 2020;
and
|
|
|
|
|
●
|
the
description of our Ordinary Shares contained in our registration statement on Form 8-A (No. 001-38544) filed with the SEC
pursuant to Section 12(b) of the Exchange Act.
|
We
are also incorporating by reference (i) all subsequent Annual Reports on Form 20-F that we file with the SEC and reports on Form
6-K that we furnish to the SEC after the date of the initial filing of and prior to the effectiveness of the registration statement
of which this prospectus forms a part, and (ii) all such Annual Reports and reports on Form 6-K that we file after the effectiveness
of the registration statement of which this prospectus forms a part, until we file a post-effective amendment indicating that
the offering of the securities made by this prospectus has been terminated (in each case, if such Form 6-K states that it is incorporated
by reference into this prospectus).
Any
statement contained in a document filed before the date of this prospectus and incorporated by reference herein shall be deemed
to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein modifies or supersedes
such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute
a part of this prospectus. Any information that we file after the date of this prospectus with the SEC and incorporated by reference
herein will automatically update and supersede the information contained in this prospectus and in any document previously incorporated
by reference in this prospectus.
You
should assume that the information appearing in this prospectus and any accompanying prospectus supplement, as well as the information
we previously filed with the SEC and incorporated by reference, is accurate as of the dates on the front cover of those documents
only.
We
will provide to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the reports
or documents that have been incorporated by reference in the prospectus contained in the registration statement not delivered
with the prospectus. We will provide these reports or documents upon written or oral request at no cost to the requester. Requests
for such documents should be made to Naked Brand Group Limited, Attn: Mr. Justin Davis-Rice, c/o Bendon Limited, 8 Airpark Drive,
Airport Oaks, Auckland 2022, New Zealand. Such documents may also be accessed free of charge on our website at www.nakedbrands.com.
Prospectus
NAKED
BRAND GROUP LIMITED
$30,000,000
Ordinary
Shares
Preference
Shares
Warrants
Debt
Securities
Units
By
this prospectus, we may offer and sell from time to time, in one or more offerings, our ordinary shares, preference shares, warrants,
debt securities, and units, which we sometimes refer to collectively as the “shelf securities,” for aggregate
gross proceeds not to exceed $30,000,000. The securities may be offered separately, together, or in series, and in amounts, at
prices, and on other terms to be determined at the time of each offering. We will provide the specific terms of the securities
to be sold in a prospectus supplement.
We
may sell the securities directly to investors, through agents designated from time to time, or to or through underwriters or dealers,
among other methods. The prospectus supplement for each offering will describe the specific methods by which we will sell the
securities. The prospectus supplement will also set forth the price to the public of such securities and the net proceeds we expect
to receive from the sale of the securities.
Our
ordinary shares trade on the Capital Market of The Nasdaq Stock Market, or “Nasdaq,” under the symbol “NAKD.”
The last sale price of our ordinary shares on June 18, 2019 was US$0.27 per share. The aggregate market value of our outstanding
ordinary shares held by non-affiliates, or our “public float,” is approximately US$16.605 million, which was calculated
based on 43,699,617 outstanding ordinary shares held by non-affiliates and on the closing price of US$0.38 per ordinary share
on June 5, 2019. We have not sold any securities pursuant to General Instruction I.B.5 of Form F-3 during the 12 calendar months
prior to and including the date of this prospectus. After the date of this prospectus, we will not sell in primary offerings under
General Instruction I.B.5 of Form F-3 securities having an aggregate market value, when added to the aggregate market value of
securities sold by us in primary offerings under General Instruction I.B.5 of Form F-3 during the 12 calendar months immediately
prior to and including the date of sale, of more than one-third of our public float.
Investing
in our securities involves risks. See “Risk Factors” beginning on page 8 to read about factors you should consider
before buying our securities.
Neither
the Securities and Exchange Commission nor any state or foreign securities commission has approved or disapproved of these securities
or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Prospectus
dated July 1, 2019
TABLE
OF CONTENTS
You
should rely only on the information contained in this prospectus and the documents we incorporate by reference in this prospectus.
We have not authorized anyone to provide you with different information. We do not take any responsibility for, and cannot provide
any assurance as to the reliability of, any other information that others may give you. We are not making an offer to sell the
securities in any jurisdiction where the offer or sale thereof is not permitted. The information contained in this prospectus
and incorporated by reference in this prospectus is accurate only as of the respective date of such information, regardless of
the time of delivery of this prospectus or of any sale or offer to sell hereunder.
To
the extent this prospectus contains summaries of the documents referred to herein, you are directed to the actual documents for
complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents
referred to herein have been filed, will be filed, or will be incorporated by reference as exhibits to the Registration Statement
of which this prospectus is a part, and you may obtain copies of such documents as described below in the section titled “Where
You Can Find Additional Information”.
Unless
otherwise stated in this prospectus, “we,” “us,” “our,” or “our company,” refers
to Naked Brand Group Limited, our subsidiaries, and our predecessor operations.
Unless
otherwise stated in this prospectus, references to dollar amounts mean United States Dollars.
This
prospectus contains references to a number of trademarks which are registered or for which we have pending applications or common
law rights. Our major trademarks include, among others, the “Naked” trademark, the Heidi Klum trademarks, the Frederick’s
of Hollywood trademarks and other related trademarks. Solely for convenience, the trademarks, service marks and trade names referred
to in this prospectus and the documents we incorporate by reference are listed without the ®, (sm) and (TM) symbols, but we
will assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks,
service marks and trade names.
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the “SEC,”
using a “shelf” registration process. Under this shelf process, we may, from time to time, sell or issue any combination
of shelf securities in one or more offerings with a maximum aggregate offering price of up to US$30,000,000.
This
prospectus provides you with a general description of the shelf securities we may offer. Each time securities are sold by us,
we will provide a prospectus supplement that will contain specific information about the terms of that offering. The prospectus
supplement may also add, update, or change information contained in this prospectus. You should read both this prospectus and
any prospectus supplement, together with the additional information described below under the heading “Where You Can
Find More Information.”
You
should rely only on the information contained or incorporated by reference in this prospectus and any prospectus supplement relating
to a particular offering. We have not authorized anyone to provide you with different information and, if provided, such information
or representations must not be relied upon as having been authorized by us. Neither this prospectus nor any prospectus supplement
nor any related issuer free writing prospectus shall constitute an offer to sell or a solicitation of an offer to buy offered
securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. This prospectus
does not contain all of the information included in the registration statement. For a more complete understanding of the offering
of the securities, you should refer to the registration statement, including its exhibits.
This
prospectus may not be used to consummate the sale of any securities unless accompanied by a prospectus supplement relating to
the securities offered.
You
should not assume that the information appearing in this prospectus is accurate as of any date other than the date on the front
cover of this prospectus. You should not assume that the information contained in the documents incorporated by reference in this
prospectus is accurate as of any date other than the respective dates of those documents. Our business, financial condition, results
of operations, and prospects may have changed since that date.
PROSPECTUS
SUMMARY
This
summary highlights key information contained elsewhere in this prospectus and in the documents incorporated in this prospectus
by reference, and is qualified in its entirety by the more detailed information herein and therein. This summary may not contain
all of the information that is important to you. You should read the entire prospectus and the documents incorporated by reference
in this prospectus, including the information in “Risk Factors” and our financial statements and the related notes
thereto, before making an investment decision.
Overview
We
operate in the highly competitive specialty retail business. We are a designer, distributor, wholesaler, and retailer of women’s
and men’s intimate apparel, as well as women’s swimwear. Our merchandise is sold through company-owned retail stores
in Australia and New Zealand; through online channels; and through wholesale partners in Australia, New Zealand, the United States
and Europe.
We
have seven reportable segments:
|
●
|
Australia
Retail: This segment covers retail and outlet stores located in Australia.
|
|
|
|
|
●
|
New
Zealand Retail: This segment covers retail and outlet stores located in New Zealand.
|
|
|
|
|
●
|
Australia
Wholesale: This segment covers the wholesale of intimates apparel to customers based in Australia.
|
|
|
|
|
●
|
New
Zealand Wholesale: This segment covers the wholesale of intimates apparel to customers based in New Zealand.
|
|
|
|
|
●
|
U.S.
Wholesale: This segment covers the wholesale of intimates apparel to customers based in the United States.
|
|
|
|
|
●
|
Europe
Wholesale: This segment covers the wholesale of intimates apparel to customers based in Europe.
|
|
|
|
|
●
|
E-commerce:
This segment covers the Company’s online retail activities.
|
In
addition, we continually explore new ways to expand its business, including through the use of new technologies, such as blockchain
technology. We are presently evaluating how these new technologies may be leveraged in the retail fashion industry. For instance,
blockchain technology might be used in the future to create highly efficient end-to-end operations from suppliers to consumers
and also to provide low cost trade finance for market participants through blockchain trading platforms. However, we have not
yet established the feasibility of, or taken any steps to progress the use of, blockchain technology in our business.
Our
Brands
Heidi
Klum
Heidi
Klum is the face and Creative Director of our flagship brands, Heidi Klum Intimates, Heidi Klum Swim, Heidi Klum Man, and Heidi
Klum Intimates Solutions. Our flagship brand, Heidi Klum Intimates collection exudes femininity, elegance and sophistication,
each piece designed with the modern woman in mind. We sell our Heidi Klum products at 63 Bendon stores in Australia, New Zealand
and Ireland and online at www.bendonlingerie.com and www.heidiklumintimates.com. Additionally, Heidi Klum products are sold in
approximately 5,000 wholesale doors in 43 countries across regions in Australia, New Zealand, United States, Europe and United
Kingdom under wholesale arrangements.
Frederick’s
of Hollywood
Since
1946, Frederick’s of Hollywood has set the standard for innovative apparel, introducing the push-up bra, the padded bra,
and black lingerie to the United States market. The brand’s rich history has led it to become one of the most recognized
in the world. Through our wholly-owned subsidiary FOH Online Corp., or “FOH,” we are the exclusive licensee
of the Frederick’s of Hollywood global online license, under which we sell Frederick’s of Hollywood intimates products,
sleepwear and loungewear products, swimwear and swimwear accessories products, and costume products. We sell our Frederick’s
of Hollwood products online at www.bendonlingerie.com and www.fredericks.com.
Naked
Naked
is an apparel and lifestyle brand company that is currently focused on innerwear products for women and men. Under its flagship
brand name and registered trademark “Naked®”, Naked designs, manufactures and sells men’s and women’s
underwear, intimate apparel, loungewear and sleepwear through retail partners and direct to consumer through its online retail
store www.wearnaked.com. Naked has a growing retail footprint for its innerwear products in premium department and specialty stores
and internet retailers in North America, including accounts such as Nordstrom, Dillard’s, Bloomingdale’s, Amazon.com
and others.
Other
Brands
Our
other brands are Bendon, Bendon Man, Davenport, Fayreform, Hickory, Lovable and Pleasure State. We sell our products at 63 Bendon
stores in Australia and New Zealand and online at www.bendonlingerie.com. Additionally, our products are sold in approximately
3,293 wholesale stores in 43 countries across regions in Australia, New Zealand, United States, Europe and United Kingdom under
wholesale arrangements.
Until
June 30, 2018, we sold Stella McCartney Lingerie and Stella McCartney Swimwear products at Bendon stores in Australia and New
Zealand and online at www.bendonlingerie.com. Additionally, Stella McCartney products were sold in wholesale doors in numerous
countries across regions in Australia, New Zealand, United States, Europe and United Kingdom under wholesale arrangements.
Our
Strengths
We
believe the following competitive strengths contribute to our leading market position and differentiate us from our competition:
Distinct,
Well-Recognized Brands
Our
iconic brands, including Heidi Klum Intimates and Swimwear and Frederick’s of Hollywood Intimates and Swimwear, have come
to represent a unique lifestyle across its targeted customers. Our brands allow us to target markets across the economic spectrum,
across demographics and across the world. We believe our flagship brands and prominent, highly-recognized creative directors provide
us with a competitive advantage.
In-Store
Experience and Store Operations
We
view our customers’ in-store experience as an important vehicle for communicating the image of each brand. We utilize visual
presentation of merchandise, in-store marketing and our sales associates to reinforce the image represented by the brands. Our
in-store marketing is designed to convey the principal elements and personality of each brand. The store design, furniture, fixtures
and music are all carefully planned and coordinated to create a unique shopping experience. Every brand displays merchandise uniformly
to ensure a consistent store experience, regardless of location. Store managers receive detailed plans designating fixture and
merchandise placement to ensure coordinated execution of the company-wide merchandising strategy. Our sales associates and managers
are a central element in creating the atmosphere of the stores by providing a high level of customer service.
Product
Development, Sourcing and Logistics
We
believe a large part of our success comes from frequent and innovative product launches, as well as launches of new collections
from our existing brands. Our merchant, design and sourcing teams have a long history of bringing innovative products to our customers.
Our key vendor partners are industry leaders in both innovation and social responsibility. We work closely together to form a
world class supply chain that is dynamic and efficient.
Highly
Experienced Leadership Team
Our
management team is led by Justin Davis-Rice, Executive Chairman, who joined Bendon in 2011 and is responsible for leading our
revenue growth. Prior to joining Bendon, Mr. Davis-Rice co-founded Pleasure State. Anna Johnson, Chief Executive Officer, brings
to us a track record of over 25 years’ experience driving growth across a number of industries, including consumer electronics,
outdoor adventure and intimate apparel. The rest of our senior management team has a wealth of retail and business experience
at Gazal, Specialty Fashion Group, and Pleasure State. We have developed a strong and collaborative culture aligned around our
goals to create the most sensual, functional and comfortable lingerie and underwear for women and men all over the world.
Growth
Strategy
Our
growth strategy involves seeking to take advantage of the following opportunities across brands and channels:
Channel
|
●
|
Opportunity
for an additional 50+ retail stores across Australia and New Zealand
|
|
|
|
|
●
|
Additional
25 Bendon outlet stores across Australia and New Zealand in the next 5 years
|
|
|
|
|
●
|
Leveraging
e-commerce to attract and educate new and existing customers
|
|
|
|
|
●
|
Targeting
e-commerce sales penetration of 40% over the medium term
|
|
|
|
|
●
|
Improving
productivity in existing wholesale accounts by gaining additional floor space
|
|
|
|
|
●
|
Selectively
adding new wholesale doors, with a focus on US markets
|
|
|
|
|
●
|
Enhancing
margins by increasing the proportion of the business derived from direct-to-consumer channels
|
Brands
|
●
|
Expanding
the brand and product offering via organic innovation and new license partnerships
|
|
|
|
|
●
|
Expanding
brand reach by leveraging our brand portfolio to extend globally, particularly in the US and EU
|
|
|
|
|
●
|
Continuing
to build our license portfolio and add new licenses in existing and tangential categories
|
Recent
Developments
On
February 14, 2019, Carole Hochman resigned from the board of directors and as our Executive Chairman, and from all other positions
she held with our subsidiaries. Ms. Hochman’s resignation was for personal reasons, and was not due to any disagreement
with us or our management on any matter relating to our operations, policies or practices (financial or otherwise).
In
March 2019, we issued 1,400,000 ordinary shares and 1,400,000 warrants to purchase ordinary shares, or the “Consultant
Warrants,” to a service provider in exchange for services. We sometimes refer to this issuance of ordinary shares and
warrants as the “March Consultant Issuance.” The Consultant Warrants have an exercise price of US$0.50 and
expire two years from the date of issuance. The exercise price and the number of shares covered by the Consultant Warrants are
subject to adjustment for stock splits, stock combinations and certain other transactions affecting the share capital as a whole.
On
March 27, 2019, we closed on the following share issuances, or the “March Financing Issuances.”
|
(1)
|
NZ$6.60
million/US$4.50 million related to the issue of 11,248,415 ordinary shares to trade creditors in satisfaction of trade payables
due to them, at an effective per share price of US$0.40.
|
|
|
|
|
(2)
|
NZ$1.25
million/US$0.85 million related to the issue of 2,119,178 ordinary shares to the holder of one of our outstanding promissory
notes in the amount of US$847,671, at an effective per share price of US$0.40 per share.
|
|
|
|
|
(3)
|
NZ$1.69
million/US$1.15 million related to the issue of 4,510,588 ordinary shares to investors in a private placement at a share price
of US$0.255. The investors also received warrants, or the “Other March Warrants,” to purchase 100% of the
number of ordinary shares for which they had subscribed. The Other March Warrants have an exercise price of US$0.306 and expire
two years from the date of issuance. The exercise price and the number of shares covered by the Other March Warrants are subject
to adjustment for stock splits, stock combinations and certain other transactions affecting the share capital as a whole.
|
|
(4)
|
NZ$4.05
million/US$2.75 million relating to the issue of 10,784,313 ordinary shares to certain accredited investors at an agreed per
share price of US$0.255, except that, to the extent an investor would beneficially own more than 9.9% of our outstanding ordinary
shares after the closing, we agreed to issue the investors a “pre-funded” warrant to purchase ordinary shares,
or a “March Pre-Funded Warrant,” in lieu of such shares. Each investor also received an “investment”
warrant to purchase 100% of the number of ordinary shares for which it had agreed to subscribe, or a “March Investment
Warrant.” We sometimes refer to the March Pre-Funded Warrants and the March Investment Warrants collectively as
the “March Warrants.” As a result, we issued 3,914,846 ordinary shares, March Pre-Funded Warrants to purchase
6,869,467 ordinary shares and March Investment Warrants to purchase 10,784,313 ordinary shares to the investors at the closing.
The March Investment Warrants have an exercise price of US$0.306 per share and expire five years from the date of issuance.
The March Pre-Funded Warrants have an exercise price of US$0.01 per share and expire five years from the date of issuance.
The exercise price and number of shares covered by the March Warrants are subject to adjustment for stock splits, stock combinations
and certain other transactions affecting the share capital as a whole, as well as for subsequent equity issuances occurring
prior to July 16, 2019, subject to certain exceptions. If the exercise price of the March Warrants is higher than the last
closing bid price of the ordinary shares, at any time starting on June 16, 2019, the March Warrants may be exercised on a
cashless basis for a number of shares equal to the Black-Scholes value of the portion of the warrant being exercised (as calculated
in accordance with the March Warrants), divided by the closing bid price as of two business days prior to the exercise date
(but not less than US$0.10). The March Warrants may not be exercised to the extent the holder and its affiliates would beneficially
own more than 9.9% of our outstanding ordinary shares after such exercise.
|
On
April 2, 2019, the board of directors appointed Anna Johnson as our Chief Executive Officer. Previously Ms Johnson was Chief Executive
Officer of Bendon Limited, the main operating entity within the Company. In connection with Ms. Johnson’s appointment, Justin
Davis-Rice was appointed as Executive Chairman and resigned as our Chief Executive Officer.
Effective
on May 13, 2019, we completed a private placement of a Secured Convertible Promissory Note, or the “Note,”
to St. George Investments LLC, or the “Noteholder,” for a purchase price of US$3,000,000, pursuant to a Securities
Purchase Agreement, or the “NSPA,” of even date. We sometimes refer to the issuance of the Note as the “May
Note Issuance.” Pursuant to the NSPA, the Note was sold with an original issue discount of the US$300,000 and we paid
US$20,000 of the Noteholder’s expenses, which amount was added to the principal balance of the Note. Accordingly, the Note
had an initial principal balance of US$3,320,000. The NSPA includes certain customary representations and warranties and covenants.
In addition, we agreed that, so long as the Note is outstanding, we will not issue any debt instrument or incur any debt, subject
to certain exceptions, including an exception for any debt incurred from a bank. The Note accrues interest at a rate of 10% per
annum, compounded daily, and matures on November 13, 2020. We have the right to prepay the Note, subject to a 15% premium. The
Note is secured by a second priority security interest in all our assets and is subordinated to the Company’s existing senior
secured credit facility with the Bank of New Zealand, or the “Bank” or “BNZ.” The Noteholder
has the right to convert the Note into ordinary shares at a conversion price of US$0.90 per share, subject to adjustment for subdivisions
or combinations of the ordinary shares. The Noteholder also has the right, beginning on December 13, 2019, to cause us to redeem
any portion of the Note, up to a maximum of US$400,000 per month.
On
May 14, 2019, we closed on NZ$2.17 million/US$1.5million share issuance of 6,000,000 shares to an investor in a private placement
at a share price of US$0.25. The investor also received warrants to purchase 1,000,000 ordinary shares. The warrants have an exercise
price of US$0.25, subject to adjustment, and expire two years from the date of issuance. We sometimes refer to the issuance of
these ordinary shares as the “May Share Issuance.”
On
May 16, 2019, we issued 653,595 ordinary shares in exchange for the cancellation of US$200,000 in debt held by a shareholder,
or an effective purchase price of US$0.306 per share. We sometimes refer to this exchange of debt for ordinary shares as the “May
Debt Exchange.”
On
June 11, 2019, we announced that we had appointed David Anderson to become our new Chief Financial Officer. Previously, Mr. Anderson
served as Head of Finance for Goodman Fielder, one of the largest consumer goods companies in New Zealand, where he oversaw all
financial aspects of the business and led numerous acquisitions. Mr. Anderson will succeed Howard Herman, our current Chief Financial
Officer, after the filing with the SEC of certain amendments to our existing registration statements, but no later than June 20,
2019. In connection with the appointment of Mr. Anderson, Mr. Herman is resigning from all positions held by him with our company.
Our
senior secured credit facility with the Bank matures on August 31, 2019 and discussions are continuing to extend the facility
beyond that point. As at October 31, 2018, there was a breach in minimum gross EBITDA ratio. As at January 31, 2019, there was
a breach of the minimum Gross EBITDA ratio and a breach of the inventory and receivables ratio. The Bank has advised that they
are currently taking these breaches under review.
Corporate
Information
Our
principal and registered office is located at Building 7B, Huntley Street, Alexandria, NSW 2015, Australia, and our telephone
number is +61 2 9384 2400. Our agent for service of process in the United States is Graubard Miller, our U.S. counsel, located
at The Chrysler Building, 405 Lexington Avenue, New York, New York 10174. Our corporate website is located at www.nakedbrands.com.
The information on our website shall not be deemed part of this registration statement.
Emerging
Growth Company
We
are an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act, or the “JOBS Act.”
As an emerging growth company, we are eligible, and have elected, to take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies. These include, but are not
limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of
2002 and reduced disclosure obligations regarding executive compensation (to the extent applicable to a foreign private issuer).
We
could remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the consummation
of our initial public offering. However, if our annual gross revenue is US$1.07 billion or more, or our non-convertible debt issued
within a three year period exceeds US$1 billion, or the market value of our ordinary shares that are held by non-affiliates exceeds
US$700 million on the last day of the second fiscal quarter of any given fiscal year, we would cease to be an emerging growth
company as of the last day of that fiscal year.
Foreign
Private Issuer
We
are a “foreign private issuer” as defined under the Securities Exchange Act of 1934, as amended, or the “Exchange
Act.” As a foreign private issuer under the Exchange Act, we are exempt from certain rules under the Exchange Act, including
the proxy rules, which impose certain disclosure and procedural requirements for proxy solicitations. Moreover, we are not required
to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic U.S. companies with securities
registered under the Exchange Act, and we are not required to comply with Regulation FD, which imposes certain restrictions on
the selective disclosure of material information. In addition, our officers, directors, and principal shareholders will be exempt
from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and the rules under
the Exchange Act with respect to their purchases and sales of our ordinary shares.
The
Nasdaq Listing Rules allow foreign private issuers, such as us, to follow home country corporate governance practices (in our
case Australian) in lieu of the otherwise applicable Nasdaq corporate governance requirements. In accordance with this exception,
we follow Australian corporate governance practices in lieu of certain of the Nasdaq corporate governance standards, as more fully
described in our Annual Report on Form 20-F for the fiscal year ended January 31, 2019, which is incorporated herein by reference.
See “Where You Can Find Additional Information” on page 28.
Risks
Affecting Our Company
In
evaluating an investment in our securities, you should carefully read this prospectus and especially consider the factors incorporated
by reference in the section titled “Risk Factors” commencing on page 8.
The
Securities We May Offer
We
may offer up to US$30,000,000 of ordinary shares, preference shares, warrants, debt securities and/or units comprised of one or
more of the foregoing classes of securities, in one or more offerings and in any combination. This prospectus provides you with
a general description of the securities we may offer. A prospectus supplement, which we will provide each time we offer securities,
will describe the specific amounts, prices and terms of these securities.
Ordinary
Shares
Each
of holder of our ordinary shares is entitled to receive notice of and to be present, to vote and to speak at general meetings.
Subject to any rights or restrictions attached to any shares, on a show of hands each holder of ordinary shares present has one
vote and, on a poll, one vote for each fully paid share held, and for each partly paid share, a fraction of a vote equivalent
to the proportion to which the share has been paid up. Voting may be in person or by proxy, attorney or representative. Two shareholders
must be present to constitute a quorum for a general meeting and no business may be transacted at any meeting except the election
of a chair and the adjournment of the meeting unless a quorum is present when the meeting proceeds to business.
Subject
to any preferential rights of any outstanding preference shares, holders of our ordinary shares are entitled to receive ratably
the dividends, if any, as may be declared from time to time by the board of directors out of legally available funds. If there
is a liquidation, dissolution or winding up of our company, holders of our ordinary shares would be entitled to share ratably
in our net assets legally available for distribution to shareholders after the payment of all our debts and liabilities and any
preferential rights of any outstanding preferred shares.
Preference
Shares
Our
constitution authorizes the issuance of preference shares, including preference shares which are, at the option of the Company
or the holder, convertible into ordinary shares. Each preference share will confer on the holder the right to receive a preferential
dividend, participate in and/or receive priority payments upon any liquidation, dissolution, or winding up, and receive a bonus
issue or capitalization of profits, each to the extent determined by our board of directors. Preference shares will have limited
voting rights. We have summarized some of the general terms and provisions of the preference shares that we may issue in “Description
of Capital Shares.” A prospectus supplement will describe the particular terms of any issue of preference shares offered
from time to time, and may supplement or change the terms outlined below.
Warrants
We
may issue warrants for the purchase of ordinary shares or preference shares or any combination thereof. We have summarized some
of the general terms and provisions of the warrants that we may issue in “Description of Warrants.” A prospectus
supplement will describe the particular terms of any warrants offered from time to time, and may supplement or change the terms
outlined below.
Debt
Securities
Subject
to an exemption from or waiver of the covenant set forth in the NSPA, and subject to any covenants in our senior credit facility
with BNZ, we may offer any combination of senior debt securities or subordinated debt securities. The subordinated debt securities
generally will be entitled to payment only after payment of our senior debt. Senior debt securities will be unsubordinated obligations
and will rank equal with all our other unsubordinated debt. Subordinated debt securities will be paid only if all payments due
under our senior indebtedness, including any outstanding senior debt securities, have been made. We may issue the senior debt
securities and the subordinated debt securities under separate indentures between us, as issuer, and the trustee or trustees identified
in a prospectus supplement. We have summarized some of the general terms and provisions of the debt securities that we may issue
in “Description of Debt Securities.” A prospectus supplement will describe the particular terms of any debt
securities offered from time to time, and may supplement or change the terms outlined below.
Units
We
may issue units comprised of one or more of the other classes of securities issued by us as described in this prospectus in any
combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit.
We have summarized some of the general terms and provisions of the warrants that we may issue in “Description of Units.”
A prospectus supplement will describe the particular terms of any units offered from time to time, and may supplement or change
the terms outlined below.
RISK
FACTORS
An
investment in our securities involves a high degree of risk. Before investing in us, you should carefully consider the risk factors
described under “Risk Factors” in the documents incorporated by reference herein, including in our most recent Annual
Report on Form 20-F filed with the SEC, together with the other information included in this prospectus and incorporated by reference
herein from our filings with the SEC, as well as any risk factors set forth under the caption “Risk Factors” in any
prospectus supplement relating to a particular offering, together with all of the other information included in such prospectus
supplement and incorporated by reference therein. If any of such risks or uncertainties occurs, our business, financial condition,
and operating results could be materially and adversely affected. Additional risks and uncertainties not currently known to us
or that we currently deem immaterial also may materially and adversely affect our business operations. As a result, the trading
price of our ordinary shares could decline and you could lose all or a part of your investment.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
The
statements contained in this prospectus that are not purely historical are forward-looking statements. Forward-looking statements
include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions, or strategies regarding the future.
In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances,
including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,”
“might,” “plan,” “possible,” “potential,” “predicts,” “project,”
“should,” “would,” and similar expressions may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include,
for example, statements about our:
|
●
|
ability
to maintain or increase profitability;
|
|
|
|
|
●
|
expectations
regarding industry trends and the size and growth rates of addressable markets;
|
|
|
|
|
●
|
reliance
on third parties for production and distribution;
|
|
|
|
|
●
|
our
business plan and our growth strategies, including plans for expansion to new markets and new products;
|
|
|
|
|
●
|
expectations
for seasonal trends;
|
|
|
|
|
●
|
results
of operations;
|
|
|
|
|
●
|
ability
to manage growth;
|
|
|
|
|
●
|
ability
to complete strategic acquisitions;
|
|
|
|
|
●
|
ability
to minimize our production and distribution costs by utilizing funding sources provided by others;
|
|
|
|
|
●
|
regulatory
or operational risks;
|
|
|
|
|
●
|
success
in retaining or recruiting, or changes required in, our officers, key employees, or directors;
|
|
|
|
|
●
|
capital
structure;
|
|
|
|
|
●
|
ability
to obtain additional financing when and if needed;
|
|
|
|
|
●
|
liquidity
and trading of our securities; and
|
|
|
|
|
●
|
status
as an emerging growth company under the JOBS Act.
|
The
forward-looking statements contained in this prospectus are based on current expectations, assumptions, and beliefs concerning
future developments and their potential effects on us. There can be no assurance that future developments will be those that have
been assumed or anticipated. These forward-looking statements are subject to a number of risks and uncertainties (some of which
are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied
by these forward-looking statements. These risks and uncertainties include, but are not limited to, those risks described from
time to time in our SEC filings and those risk factors described under the heading “Risk Factors” herein and
in any prospectus supplement relating to a particular offering. Should one or more of these risks or uncertainties materialize,
or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking
statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, except as may be required under applicable securities laws.
USE
OF PROCEEDS
Unless
otherwise indicated in an accompanying prospectus supplement, the net proceeds from the sale of the securities offered hereby
will be used for general corporate purposes, which may include working capital, capital expenditures, debt repayment, or acquisitions.
In the event that any net proceeds are not immediately applied, we may temporarily hold them as cash, deposit them in banks or
invest them in cash equivalents or securities. We have not allocated any portion of the net proceeds for any particular use at
this time. Specific information concerning the use of proceeds from the sale of any securities will be included in the prospectus
supplement relating to the particular offering in which they are sold.
DILUTION
The
specific transaction or terms upon which securities covered by this prospectus may be issued is not known at this time. Each time
we sell securities under this prospectus, we will provide a prospectus supplement that will contain certain specific information
about the terms of that offering. In the event that there is substantial disparity between the public offering price of the securities
to be issued and the effective cost to directors or senior management or affiliated persons of equity securities acquired by them
during the last five years, or which they have the right to acquire, a comparison of the public contribution in the proposed public
offering and the effective cash contributions of such persons, as well as the amount and percentage of immediate dilution resulting
from the offering, will be contained in the prospectus supplement. We will also disclose the amount and percentage of immediate
dilution resulting from the offering, computed as the difference between the offering price per share and the net book value per
share for the equivalent class of security, as of the most recent balance sheet date.
CAPITALIZATION
AND INDEBTEDNESS
The
following table sets forth our capitalization at January 31, 2019 on an historical basis and on a pro forma basis, after giving
effect to the March Consultant Issuance, the March Financing Issuances, the May Note Issuance, the May Share Issuance and the
May Debt Exchange. The information presented in the capitalization table below is unaudited.
|
|
Historical
|
|
|
Pro Forma
|
|
As at January 31, 2019
|
|
NZ$ ‘000
|
|
|
US$ ‘000(5)
|
|
|
NZ$ ‘000
|
|
|
US$ ‘000(5)
|
|
Borrowings(1)(2)
|
|
|
20,967
|
|
|
|
14,467
|
|
|
|
23,767
|
|
|
|
16,417
|
|
Share Capital(1)(3)
|
|
|
134,183
|
|
|
|
92,586
|
|
|
|
145,895
|
|
|
|
100,536
|
|
Fair Value of Warrants(4)
|
|
|
-
|
|
|
|
-
|
|
|
|
4,348
|
|
|
|
3,000
|
|
Accumulated Losses
|
|
|
(121,651
|
)
|
|
|
(83,939
|
)
|
|
|
(121,651
|
)
|
|
|
(83,939
|
)
|
Reserves
|
|
|
(2,013
|
)
|
|
|
(1,389
|
)
|
|
|
(2,013
|
)
|
|
|
(1,389
|
)
|
Total Capitalization
|
|
|
31,486
|
|
|
|
21,725
|
|
|
|
50,346
|
|
|
|
34,625
|
|
|
(1)
|
Reflects
the following:
|
|
a.
|
NZ$1.25
million/US$0.85 million related to the issue of 2,119,178 ordinary shares to the holder of one of the outstanding promissory
notes in the amount of $847,671 at US$0.40 per share.
|
|
|
|
|
b.
|
On
the May 16, 2019, the Group issued 635,585 ordinary shares in exchange for the cancellation of a NZ$0.3 million/US$0.2 million
debt held by a shareholder.
|
|
(2)
|
Reflects
the completion, on May 13, 2019, of a private placement of a secured convertible promissory note for a purchase price of NZ$4.35
million/US$3 million. The note accrues interest at 10% per annum and matures on November 13, 2020.
|
|
|
|
|
(3)
|
Reflects
the following:
|
|
a.
|
NZ$6.60
million/US$4.50 million related to the issue of 11,248,415 ordinary shares to trade creditors in satisfaction of trade payables
due to them, at an effective per share price of US$0.40.
|
|
|
|
|
b.
|
NZ$1.69
million/US$1.15 million related to the issue of 4,510,588 ordinary shares to investors in a private placement at a share price
of US$0.255.
|
|
c.
|
NZ$4.05
million/US$2.75 million relating to the issue to certain accredited investors of 10,784,313 ordinary shares at an agreed per
share price of US$0.255, except that, to the extent an investor would beneficially own more than 9.9% of our outstanding ordinary
shares after the closing, we agreed to issue the investor “pre-funded” warrants in lieu of such shares. Each investor
also received an “investment” warrant to purchase 100% of the number of ordinary shares for which it had agreed
to subscribe. As a result, we issued 3,914,846 ordinary shares, “pre-funded” warrants to purchase 6,869,467 ordinary
shares and “investment” warrants to purchase 10,784,313 ordinary shares to the investors at the closing.
|
|
|
|
|
d.
|
The
closing, on May 14, 2019, on a NZ$2.17 million/US$1.5million share issuance of 6,000,000 shares to investors in a private
placement at a share price of US$0.25. The investor also received a warrant to purchase 1,000,000 ordinary shares.
|
|
(4)
|
Capitalization
is adjusted by NZ$4.348 million/US$3million to recognize a derivative liability in relation to the issue of 31,286,368 warrants
at $0.27 per warrant on June 18, 2019.
|
|
|
|
|
(5)
|
In
this prospectus certain New Zealand dollar amounts have been translated into United States dollars at the rate of NZ$1 = USD$0.69.
Such translations should not be construed as representations that the New Zealand dollar amounts represent, or have been or
could be converted into, United States dollars at that or any other rate.
|
You
should read this table in conjunction with our consolidated financial statements as at and for the year ended January 31, 2019,
which are incorporated by reference in this prospectus.
DESCRIPTION
OF CAPITAL SHARES
General
Australia
does not have a limit on the authorized share capital that may be issued and does not recognize the concept of par value. Subject
to the restrictions on the issue of securities in our constitution, the Corporations Act 2001 (Cth) of Australia, or the “Corporations
Act,” and the rules governing the listing of our securities on the Nasdaq Capital Market, our directors are entitled
to issue and cancel shares in our capital, grant options over unissued shares, and settle the manner in which fractions of a share
are to be dealt with. The directors may decide the persons to whom, and the terms on which, shares are issued or options are granted
as well as the rights and restrictions that attach to those shares or options.
As
of June 18, 2019, 59,487,636 ordinary shares are issued and outstanding, which does not include an aggregate of (i) 31,286,368
ordinary shares underlying outstanding warrants that have not been exercised as of such date and (ii) 2,968,433 ordinary shares
underlying outstanding convertible promissory notes that have not been converted as of such date (assuming all outstanding principal
and interest thereon through such date is converted at the initial conversion price of $0.90 per share, without regard to any
limitations on such conversion).
Ordinary
Shares
Voting
Rights
Each
of holder of our ordinary shares is entitled to receive notice of and to be present, to vote and to speak at general meetings.
Subject to any rights or restrictions attached to any shares, on a show of hands each holder of ordinary shares present has one
vote and, on a poll, one vote for each fully paid share held, and for each partly paid share, a fraction of a vote equivalent
to the proportion to which the share has been paid up. Voting may be in person or by proxy, attorney or representative.
Two
shareholders must be present to constitute a quorum for a general meeting and no business may be transacted at any meeting except
the election of a chair and the adjournment of the meeting unless a quorum is present when the meeting proceeds to business.
Dividend
Rights
Holders
of our ordinary shares are entitled to receive such dividends as may be declared by the directors, subject to the preferential
dividend rights of the preference shares, if any. If the directors determine that a final or interim dividend is payable, it is
(subject to the terms of issue on any shares or class of shares) paid on all shares proportionate to the amount for the time being
paid on each share. Dividends may be paid by cash, electronic transfer, or any other method as the board determines.
The
directors have the power to capitalize and distribute the whole or part of the amount from time to time standing to the credit
of any reserve account or otherwise available for distribution to shareholders. The capitalization and distribution must be in
the same proportions which the shareholders would be entitled to receive if distributed by way of a dividend.
Subject
to the rules of Nasdaq and the Corporations Act, the directors may pay a dividend out of any fund or reserve or out of our profits.
Variation
of Class Rights
The
Corporations Act provides that if a company has a constitution that sets out the procedure for varying or cancelling rights attached
to shares in a class of shares, those rights may be varied or cancelled only in accordance with the procedure.
The
rights attached to our ordinary shares may only be varied with the consent in writing of members holding at least three-quarters
of the shares of that class, or with the sanction of a special resolution passed at a separate meeting of the holders of shares
of that class.
Rights
of Non-Resident or Foreign Shareholders
There
are no specific limitations in the Corporations Act which restrict the acquisition, ownership, or disposal of shares in an Australian
company by non-resident or foreign shareholders. The Foreign Acquisitions and Takeovers Act 1975 (Cth) regulates investment in
Australian companies and may restrict the acquisition, ownership, and disposal of our shares by non-resident or foreign shareholders.
Preference
Shares
As
of June 18, 2019, there are no preference shares issued or outstanding. If issued, the preference shares will have such rights
and preferences as determined by our board of directors in accordance with our constitution and set forth in the terms of issue
for the shares. The following outlines some of the general terms and provisions of preference shares that we may issue from time
to time. Additional or different terms of the preference shares will be set forth in the applicable prospectus supplement.
We
will file as an exhibit to the registration statement of which this prospectus forms a part, or will incorporate by reference
from reports that we file with the SEC, the form of any subscription agreement that describes the terms of the issue of preference
shares we are offering before the issuance of the preference shares. The summaries of material provisions of the preference shares
are subject to, and qualified in their entirety by reference to, all of the provisions of our constitution and the subscription
agreement applicable to a particular issue of preference shares. We urge you to read the applicable prospectus supplements, as
well as the complete agreement and constitution that contains the terms of the issue of preference shares.
General
The
prospectus supplement relating to a particular issue of preference shares will describe the terms of that issue of preference
shares and the price or prices at which we will offer the shares of that issue of preference shares. The description may include:
|
●
|
the
title of the issue of preference shares and the number of shares offered;
|
|
|
|
|
●
|
the
preferential dividend rate, the terms and conditions relating to the payment of dividends on the preference shares;
|
|
|
|
|
●
|
whether
the preference shares are redeemable, and the terms and conditions relating to any such redemption;
|
|
|
|
|
●
|
whether
the preference shares are convertible into ordinary shares, and the terms and conditions relating to any such conversion;
and
|
|
|
|
|
●
|
any
liquidation preference of the preference shares.
|
Voting
Rights
Holders
of preference shares generally will have no voting rights except as set forth below. On each matter on which holders of preference
shares are entitled to vote, each preference share will be entitled to one vote, or will be entitled to the number of votes specified
in the terms of issue for the share.
Preference
shares may vote at a general meeting only in the following circumstances: (i) on a proposal to reduce the share capital of the
Company, or that would affect the rights attached to the preference share, or to wind up the Company or for the disposal of the
whole of the property, business, and undertaking of the Company, (ii) on a proposal to approve the terms of a buy-back agreement,
(iii) during the period in which dividends on any preference shares are in arrears, (iv) during the winding up of the Company,
and (v) in other circumstances as required by the listing rules of Nasdaq or another exchange that is our primary stock exchange.
Dividend
Rights
Holders
of our preference shares are entitled to receive a preferential dividend, in priority to the payment of any dividend on the ordinary
shares, at a rate (which may be fixed or variable) and on the basis (including whether cumulative or not) decided by our board
of directors at the time of issue. Subject to the rules of Nasdaq, the directors may pay a dividend out of any fund or reserve
or out of profits derived from any source.
The
directors may decide at the time of issue to designate a bonus issue or to capitalize and distribute the Company’s profits
in favor of the holders of preference shares. The bonus issue, or the capitalization and distribution, must be in the same proportions
which the shareholders would be entitled to receive if distributed by way of a dividend.
Conversion
and Redemption Rights
The
board of directors may decide at the time of issue to designate an issue of preference shares as redeemable. Preference shares
may be convertible into our ordinary shares, as and if designated by the board of directors at the time of issue.
Liquidation
Rights
In
the event of our voluntary or involuntary liquidation, dissolution, or winding up, the holders preference shares may be entitled
to participate with the ordinary shares in the profits and assets of the company, and/or may be entitled to payment in priority
to the ordinary shares of the amount of any accrued but unpaid dividend or any other additional amount, if and to the extent the
directors decide at the time of issue.
Outstanding
Warrants
Naked
Warrants
As
part of the transactions pursuant to which we acquired our wholly owned subsidiaries Bendon Limited and Naked Brand Group Inc.
in June 2018, or the “Transactions,” we assumed warrants to purchase up to 637,730 ordinary shares, or the
“Naked Warrants,” which were held by the former Naked Brand Group Inc. stockholders. The exercise price and
number of shares covered by the Naked Warrants are subject to adjustment for stock splits, stock combinations and certain other
transactions affecting the share capital as a whole.
PIPE
Warrants
Pursuant
to our financing plan prior to the consummation of the Transactions, we entered into securities purchase agreements with certain
investors for the purchase and sale of warrants to purchase up to an aggregate of 3,880,262 ordinary shares, or the “PIPE
Warrants.” The PIPE Warrants entitle the holders to purchase ordinary shares at a weighted average exercise price of
US$5.62 per share, subject to adjustment as discussed below. The PIPE Warrants are exercisable at any time for periods of between
one and five years.
With
respect to warrants to purchase an aggregate of 800,000 ordinary shares, if our ordinary shares are traded, listed, or quoted
on any U.S. market or electronic exchange, and the closing per-share sales price of the ordinary shares for any ten (10) consecutive
trading days exceeds US$10.00 (subject to adjustment for forward and reverse splits, recapitalizations, share dividends and the
like), then we may call for cancellation of all or any portion of such warrants for which a notice of exercise has not yet been
delivered to us, for consideration equal to US$0.01 per warrant. The right to exercise will be forfeited unless these warrants
are exercised prior to the date specified in the call notice. On and after the call date, a record holder of such warrant will
have no further rights except to receive the call price for such holder’s warrant upon surrender of such warrant.
Additionally,
if the resale of the ordinary shares issuable upon exercise of the PIPE Warrants is not covered by an effective registration statement
or an exemption from registration at any time after December 19, 2018, the holder of such warrants shall be afforded cashless
exercise rights. In such event, the holder would pay the exercise price by surrendering the warrants for that number of ordinary
shares equal to the quotient obtained by dividing (x) the product of the number of ordinary shares underlying the warrants, multiplied
by the exercise price of the warrants by (y) the daily volume weighted average price of the ordinary shares on the primary U.S.
trading market on which the ordinary shares are then listed or quoted as reported by Bloomberg L.P. on the trading date immediately
prior to the date of exercise.
The
number of ordinary shares issuable on exercise of the outstanding warrants and exercise price of such warrants may be adjusted
in certain circumstances including in the event of a share split, bonus issue, recapitalization, reorganization, merger, or consolidation.
October
Warrants
In
a private placement completed in October 2018, we offered and sold the October Warrants to purchase 2,200,000 ordinary shares
at an exercise price of US$1.55 per share. The Placement Warrants expire three years from the date of issuance. The exercise price
and number of shares covered by the Placement Warrants are subject to adjustment for stock splits, stock combinations and certain
other transactions affecting the share capital as a whole.
March
Warrants
In
a private placement completed in March 2019, we offered and sold the March Pre-Funded Warrants to purchase 6,869,467 ordinary
shares and the March Investment Warrants to purchase 10,784,313 ordinary shares. The March Investment Warrants have an exercise
price of US$0.306 per share and expire five years from the date of issuance. The March Pre-Funded Warrants have an exercise price
of US$0.01 per share and expire five years from the date of issuance. The exercise price and number of shares covered by the March
Warrants are subject to adjustment for stock splits, stock combinations and certain other transactions affecting the share capital
as a whole, as well as for subsequent equity issuances occurring prior to the 90th day after the date of this prospectus, subject
to certain exceptions. If the exercise price of the March Warrants is higher than the last closing bid price of the ordinary shares,
at any time starting 60 days after the date of this prospectus, the March Warrants may be exercised on a cashless basis for a
number of shares equal to the Black-Scholes value of the portion of the warrant being exercised (as calculated in accordance with
the March Warrants), divided by the closing bid price as of two business days prior to the exercise date (but not less than US$0.10).
The March Warrants may not be exercised to the extent the holder and its affiliates would beneficially own more than 9.9% of our
outstanding ordinary shares after such exercise.
Consultant
and Other March Warrants
In
March 2019, we issued the Consultant Warrants to purchase 1,400,000 ordinary shares, at an exercise price of US$0.50 of per share,
and the Other March Warrants to purchase 4,510,588 ordinary shares, at an exercise price of US$0.306 per share. The Consultant
Warrants and the Other March Warrants expire two years from the date of issuance. The exercise price and the number of shares
covered by the Consultant Warrants and the Other March Warrants are subject to adjustment for stock splits, stock combinations
and certain other transactions affecting the share capital as a whole.
Warrants
Generally
Our
warrants may be exercised upon delivery of an exercise notice, duly signed by the warrant holder, accompanied by full payment
of the exercise price, in US dollars, in same day cleared funds that will not be reversed, delivered into the Company’s
bank account, free and clear of any restriction, condition, set-off, deduction, or withholding.
The
warrant holders do not have the rights or privileges of holders of ordinary shares and any voting rights until they exercise their
warrants and receive ordinary shares. After the issuance of ordinary shares upon exercise of the warrants, each holder will be
entitled to one vote for each share held of record on all matters to be voted on by stockholders.
Outstanding
Convertible Note
Effective
on May 13, 2019, we completed a private placement of the Note for a purchase price of US$3,000,000, pursuant to the NSPA of even
date. Pursuant to the NSPA, the Note was sold with an original issue discount of the US$300,000 and we paid US$20,000 of the Noteholder’s
expenses, which amount was added to the principal balance of the Note. Accordingly, the Note had an initial principal balance
of US$3,320,000. The Note accrues interest at a rate of 10% per annum, compounded daily, and matures on November 13, 2020. The
Noteholder has the right to convert the Note into ordinary shares at a conversion price of US$0.90 per share, subject to adjustment
for subdivisions or combinations of the ordinary shares.
Exchange
Act Registration; Listing of our Securities
Our
ordinary shares are registered under the Exchange Act and trade on Nasdaq under the symbol “NAKD.” The last sale price
of our ordinary shares on June 18, 2019 was US$0.27 per share. As of the date of this prospectus, no other class
of securities that we may offer hereunder is listed on any national securities exchange or automated quotation system.
Our
Transfer Agent
The
transfer agent for our ordinary shares is Continental Stock Transfer & Trust Company. The transfer agent and registrar for
any issue of preference shares will be set forth in the applicable prospectus supplement.
DESCRIPTION
OF WARRANTS
We
may issue warrants for the purchase of ordinary or preference shares or any of the other securities that may be sold under this
prospectus, or any combination of these securities. Warrants may be issued independently or together with other securities and
may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement
to be entered into between a warrant agent and us. The warrant agent will act solely as our agent in connection with the warrants
and will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants.
The following outlines some of the general terms and provisions of the warrants that we may issue from time to time. Additional
or different terms of the warrants and the applicable warrant agreement will be set forth in the applicable prospectus supplement.
We
will file as an exhibit to the registration statement of which this prospectus is a part of, or will incorporate by reference
from reports that we file with the SEC, the form of warrant agreement that describes the terms of the series of warrants we are
offering before the issuance of those warrants. The following summaries of material provisions of the warrants are subject to,
and qualified in their entirety by reference to, all of the provisions of the warrant agreement applicable to a particular series
of warrants. We urge you to read the applicable prospectus supplements, as well as the complete warrant agreement that contains
the terms of the series of warrants.
General
The
prospectus supplement relating to a particular issue of warrants will describe the terms of those warrants and the price or prices
at which will offer the warrants. The description may include:
|
●
|
the
title of the warrants;
|
|
|
|
|
●
|
the
aggregate number of warrants offered;
|
|
|
|
|
●
|
the
designation and/or terms of the securities purchasable upon exercise of the warrants;
|
|
|
|
|
●
|
if
applicable, the designation and/or terms of the securities that the warrants are issued
with and the number of warrants issued with each security;
|
|
|
|
|
●
|
if
applicable, the date from and after which the warrants and any securities issued with
the warrants will be separately transferable;
|
|
|
|
|
●
|
the
amount and price of securities that may be purchased upon exercise of a warrant;
|
|
|
|
|
●
|
the
dates on which the right to exercise the warrants commence and expire;
|
|
|
|
|
●
|
if
applicable, the minimum or maximum amount of the warrants that may be exercised at any
one time;
|
|
|
|
|
●
|
whether
the warrants represented by the warrant certificates or, if applicable, the securities
that may be issued upon exercise of the warrants, will be issued in registered or bearer
form;
|
|
|
|
|
●
|
if
applicable, information relating to book-entry procedures;
|
|
|
|
|
●
|
if
applicable, a discussion of material U.S. Federal income tax considerations
|
|
|
|
|
●
|
anti-dilution
provisions of the warrants, if any;
|
|
|
|
|
●
|
redemption
or call provisions, if any, applicable to the warrants; and
|
|
|
|
|
●
|
any
additional terms of the warrants, including terms, procedures and limitations relating
to the exchange and exercise of the warrants.
|
Warrant
holders will not have the rights or privileges of holders of ordinary shares or any voting rights until they exercise their warrants
and receive ordinary shares. After the issuance of ordinary shares upon exercise of the warrants, each holder will be entitled
to one vote for each share held of record on all matters to be voted on by shareholders.
DESCRIPTION
OF DEBT SECURITIES
Subject
to the covenants set forth in the NSPA and the Note (described above), and any covenants in our senior credit facility with BNZ,
we may issue debt securities, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible
debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus,
we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement.
The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context
requires otherwise, whenever we refer to the indentures, we also are referring to any supplemental indentures that specify the
terms of a particular series of debt securities.
We
will issue the senior debt securities under the senior indenture that we will enter into with the trustee to be named in the senior
indenture. We will issue the subordinated debt securities under the subordinated indenture that we will enter into with the trustee
to be named in the subordinated indenture. The indentures will be qualified under the Trust Indenture Act of 1939. We use the
term “debenture trustee” to refer to either the trustee under the senior indenture or the trustee under the subordinated
indenture, as applicable. We have filed forms of indentures as exhibits to the registration statement of which this prospectus
is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered
will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference
from reports that we file with the SEC.
The
following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures
are subject to, and qualified in their entirety by reference to, all of the provisions of the indenture applicable to a particular
series of debt securities. We urge you to read the applicable prospectus supplements, as well as the complete indenture that contains
the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated
indenture are identical.
General
We
will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:
|
●
|
the
title;
|
|
|
|
|
●
|
the
principal amount being offered, and if a series, the total amount authorized and the
total amount outstanding;
|
|
|
|
|
●
|
any
limit on the amount that may be issued;
|
|
|
|
|
●
|
whether
or not we will issue the series of debt securities in global form, the terms and who
the depositary will be;
|
|
|
|
|
●
|
the
maturity date;
|
|
|
|
|
●
|
whether
and under what circumstances, if any, we will pay additional amounts on any debt securities
held by a person who is not a U.S. person for tax purposes, and whether we can redeem
the debt securities if we have to pay such additional amounts;
|
|
|
|
|
●
|
the
annual interest rate, which may be fixed or variable, or the method for determining the
rate and the date interest will begin to accrue, the dates interest will be payable and
the regular record dates for interest payment dates or the method for determining such
dates;
|
|
|
|
|
●
|
whether
the interest is payable in property other than cash, including in securities of ours,
or by increasing the principal amount of the debt securities;
|
|
|
|
|
●
|
whether
or not the debt securities will be secured or unsecured, and the terms of any secured
debt;
|
|
|
|
|
●
|
the
terms of the subordination of any series of subordinated debt;
|
|
|
|
|
●
|
the
place where payments will be payable;
|
|
|
|
|
●
|
restrictions
on transfer, sale or other assignment, if any;
|
|
|
|
|
●
|
our
right, if any, to defer payment of interest and the maximum length of any such deferral
period;
|
|
●
|
the
date, if any, after which, and the price at which, we may, at our option, redeem the
series of debt securities pursuant to any optional or provisional redemption provisions
and the terms of those redemption provisions;
|
|
|
|
|
●
|
the
date, if any, on which, and the price at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder’s
option to purchase, the series of debt securities and the currency or currency unit in
which the debt securities are payable;
|
|
|
|
|
●
|
whether
the indenture will restrict our ability to incur additional indebtedness, issue additional
securities, create liens, pay dividends and make distributions in respect of our capital
stock, redeem capital stock, make investments or other restricted payments, sell or otherwise
dispose of assets, enter into sale-leaseback transactions, engage in transactions with
shareholders and affiliates, or effect a consolidation or merger;
|
|
|
|
|
●
|
whether
the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based,
asset-based or other financial ratios;
|
|
|
|
|
●
|
a
discussion of any material U.S. Federal income tax considerations applicable to the debt
securities;
|
|
|
|
|
●
|
information
describing any book-entry features;
|
|
|
|
|
●
|
provisions
for a sinking fund purchase or other analogous fund, if any;
|
|
|
|
|
●
|
the
applicability of the provisions in the indenture on discharge;
|
|
|
|
|
●
|
whether
the debt securities are to be offered at a price such that they will be deemed to be
offered at an “original issue discount” as defined in paragraph (a) of Section
1273 of the Internal Revenue Code;
|
|
|
|
|
●
|
the
denominations in which we will issue the series of debt securities, if other than denominations
of $1,000 and any integral multiple thereof;
|
|
|
|
|
●
|
the
currency of payment of debt securities if other than U.S. dollars and the manner of determining
the equivalent amount in U.S. dollars; and
|
|
|
|
|
●
|
any
other specific terms, preferences, rights or limitations of, or restrictions on, the
debt securities, including any additional events of default or covenants provided with
respect to the debt securities, and any terms that may be required by us or advisable
under applicable laws or regulations.
|
Conversion
or Exchange Rights
We
will set forth in the prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable
for our ordinary shares or our other securities. We will include provisions as to whether conversion or exchange is mandatory,
at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our ordinary
shares or our other securities that the holders of the series of debt securities receive would be subject to adjustment.
Consolidation,
Merger or Sale
Unless
we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indentures will not
contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all
or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under
the indentures or the debt securities, as appropriate. If the debt securities are convertible into or exchangeable for our other
securities or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property
must make provisions for the conversion of the debt securities into securities that the holders of the debt securities would have
received if they had converted the debt securities before the consolidation, merger or sale.
Events
of Default Under the Indenture
Unless
we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events
of default under the indentures with respect to any series of debt securities that we may issue:
|
●
|
if
we fail to pay interest when due and payable and our failure continues for 90 days and
the time for payment has not been extended or deferred;
|
|
|
|
|
●
|
if
we fail to pay the principal, premium or sinking fund payment, if any, when due and payable
and the time for payment has not been extended or delayed;
|
|
|
|
|
●
|
if
we fail to observe or perform any other covenant contained in the debt securities or
the indentures, other than a covenant specifically relating to another series of debt
securities, and our failure continues for 90 days after we receive notice from the debenture
trustee or holders of at least a majority of the aggregate principal amount of the outstanding
debt securities of the applicable series; and
|
|
|
|
|
●
|
if
specified events of bankruptcy, insolvency or reorganization occur.
|
If
an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified
in the last bullet point above, the debenture trustee or the holders of at least a majority of the aggregate principal amount
of the outstanding debt securities of that series, by notice to us in writing, and to the debenture trustee if notice is given
by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately.
If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued
interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action
on the part of the debenture trustee or any holder.
The
holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event
of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal,
premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver
shall cure the default or event of default.
Subject
to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the debenture trustee
will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of
the holders of the applicable series of debt securities, unless such holders have offered the debenture trustee reasonable indemnity.
The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the
time, method and place of conducting any proceeding for any remedy available to the debenture trustee, or exercising any trust
or power conferred on the debenture trustee, with respect to the debt securities of that series, provided that:
|
●
|
the
direction so given by the holder is not in conflict with any law or the applicable indenture;
and
|
|
|
|
|
●
|
subject
to its duties under the Trust Indenture Act of 1939, the debenture trustee need not take
any action that might involve it in personal liability or might be unduly prejudicial
to the holders not involved in the proceeding.
|
A
holder of the debt securities of any series will have the right to institute a proceeding under the indentures or to appoint a
receiver or trustee, or to seek other remedies only if:
|
●
|
the
holder has given written notice to the debenture trustee of a continuing event of default
with respect to that series;
|
|
|
|
|
●
|
the
holders of at least a majority of the aggregate principal amount of the outstanding debt
securities of that series have made written request, and such holders have offered reasonable
indemnity to the debenture trustee to institute the proceeding as trustee; and
|
|
|
|
|
●
|
the
debenture trustee does not institute the proceeding, and does not receive from the holders
of a majority in aggregate principal amount of the outstanding debt securities of that
series other conflicting directions within 90 days after the notice, request and offer.
|
These
limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium,
if any, or interest on, the debt securities.
We
will periodically file statements with the debenture trustee regarding our compliance with specified covenants in the indentures.
Modification
of Indenture; Waiver
We
and the debenture trustee may change an indenture without the consent of any holders with respect to specific matters:
|
●
|
to
fix any ambiguity, defect or inconsistency in the indenture;
|
|
|
|
|
●
|
to
comply with the provisions described above under “Description of Debt Securities
— Consolidation, Merger or Sale”;
|
|
|
|
|
●
|
to
comply with any requirements of the SEC in connection with the qualification of any indenture
under the Trust Indenture Act of 1939;
|
|
|
|
|
●
|
to
add to, delete from or revise the conditions, limitations and restrictions on the authorized
amount, terms or purposes of issue, authentication and delivery of debt securities, as
set forth in the indenture;
|
|
|
|
|
●
|
to
provide for the issuance of and establish the form and terms and conditions of the debt
securities of any series as provided under “Description of Debt Securities —
General,” to establish the form of any certifications required to be furnished
pursuant to the terms of the indenture or any series of debt securities, or to add to
the rights of the holders of any series of debt securities;
|
|
|
|
|
●
|
to
evidence and provide for the acceptance of appointment hereunder by a successor trustee;
|
|
|
|
|
●
|
to
provide for uncertificated debt securities in addition to or in place of certificated
debt securities and to make all appropriate changes for such purpose;
|
|
|
|
|
●
|
to
add to our covenants such new covenants, restrictions, conditions or provisions for the
protection of the holders, and to make the occurrence, or the occurrence and the continuance,
of a default in any such additional covenants, restrictions, conditions of or provisions
for an event of default; or
|
|
|
|
|
●
|
to
change anything that does not materially adversely affect the interests of any holder
of debt securities of any series.
|
In
addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the debenture trustee
with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities
of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular
series of debt securities, we and the debenture trustee may make the following changes only with the consent of each holder of
any outstanding debt securities affected:
|
●
|
extending
the fixed maturity of the series of debt securities;
|
|
|
|
|
●
|
reducing
the principal amount, reducing the rate of or extending the time of payment of interest,
or reducing any premium payable upon the redemption of any debt securities; or
|
|
|
|
|
●
|
reducing
the percentage of debt securities, the holders of which are required to consent to any
amendment, supplement, modification or waiver.
|
Discharge
Each
indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities,
except for specified obligations, including obligations to:
|
●
|
register
the transfer or exchange of debt securities of the series;
|
|
|
|
|
●
|
replace
stolen, lost or mutilated debt securities of the series;
|
|
|
|
|
●
|
maintain
paying agencies;
|
|
|
|
|
●
|
hold
monies or other property for payment in trust;
|
|
|
|
|
●
|
recover
excess money held by the debenture trustee;
|
|
|
|
|
●
|
compensate
and indemnify the debenture trustee; and
|
|
|
|
|
●
|
appoint
any successor trustee.
|
In
order to exercise our rights to be discharged, we must deposit with the debenture trustee money or government obligations (or,
if the debt securities are payable otherwise than in cash, we must have made other arrangements satisfactory to the debenture
trustee for payment in property other than cash), sufficient to pay all the principal of, any premium, if any, and interest on
the debt securities of the series on the dates payments are due.
Form,
Exchange and Transfer
We
will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in
the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indentures provide that
we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited
with, or on behalf of, The Depository Trust Company or another depositary named by us and identified in a prospectus supplement
with respect to that series. See “Legal Ownership of Securities” for a further description of the terms relating
to any book-entry securities.
At
the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described
in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for
other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.
Subject
to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or
with the form of transfer endorsed thereon duly executed, if so required by us or the security registrar, at the office of the
security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the
debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer
or exchange, but we may require payment of any taxes or other governmental charges.
We
will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar,
that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation
of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required
to maintain a transfer agent in each place of payment for the debt securities of each series.
If
we elect to redeem the debt securities of any series, we will not be required to:
|
●
|
issue,
register the transfer of, or exchange any debt securities of that series during a period
beginning at the opening of business 15 days before the day of mailing of a notice of
redemption of any debt securities that may be selected for redemption and ending at the
close of business on the day of the mailing; or
|
|
|
|
|
●
|
register
the transfer of or exchange any debt securities so selected for redemption, in whole
or in part, except the unredeemed portion of any debt securities we are redeeming in
part.
|
Information
Concerning the Debenture Trustee
The
debenture trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform
only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the
debenture trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own
affairs. Subject to this provision, the debenture trustee is under no obligation to exercise any of the powers given it by the
indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the
costs, expenses and liabilities that it might incur.
Payment
and Paying Agents
Unless
we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on
any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered
at the close of business on the regular record date for the interest.
We
will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments
by check that we will mail to the holder or by wire transfer to certain holders (or, if the debt securities are payable otherwise
than in cash, in accordance with provisions set forth in the prospectus supplement). Unless we otherwise indicate in the applicable
prospectus supplement, we will designate the corporate trust office of the debenture trustee in the City of New York as our sole
paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement
any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying
agent in each place of payment for the debt securities of a particular series.
All
money or other property we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or
interest on any debt securities that remains unclaimed at the end of two years after such principal, premium, if any, or interest
has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment
thereof.
Governing
Law
The
indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except
to the extent that the Trust Indenture Act of 1939 is applicable.
Subordination
of Subordinated Debt Securities
The
subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain of our other
indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of subordinated
debt securities that we may issue, nor does it limit us from issuing any other secured or unsecured debt.
DESCRIPTION
OF UNITS
We
may offer units comprised of any of the other securities described in this prospectus in any combination. Each unit will be issued
so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have
the rights and obligations of a holder of each included security. The units may be issued under unit agreements to be entered
into between us and a bank or trust company, as unit agent, as detailed in the prospectus supplement relating to units being offered.
We
will file as exhibits to the registration statement of which this prospectus is a part of, or will incorporate by reference from
reports that we file with the SEC, the form of unit agreement, if any, that describes the terms of the series of units we are
offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material
terms and provisions of the units are subject to, and qualified in their entirety by reference to, all the provisions of the unit
agreement, if any, and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable
prospectus supplements related to the particular series of units that we may offer under this prospectus, as well as the complete
unit agreement, if any, and any supplemental agreements that contain the terms of the units.
The
prospectus supplement relating to a particular issue of units will describe the terms of those units and the price or prices at
which we will offer the units. The description may include:
|
●
|
the
designation and terms of the units and of the securities comprising the units, including
whether and under what circumstances the securities comprising the units may be held
or transferred separately;
|
|
|
|
|
●
|
a
description of the terms of any unit agreement governing the units;
|
|
|
|
|
●
|
a
description of the provisions for the payment, settlement, transfer or exchange of the
units;
|
|
|
|
|
●
|
a
discussion of material federal income tax considerations, if applicable; and
|
|
●
|
whether
the units will be issued in fully registered or global form.
|
LEGAL
OWNERSHIP OF SECURITIES
We
can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater
detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable
trustee, depositary or warrant agent maintain for this purpose as the “holders” of those securities. These persons
are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in
securities that are not registered in their own names, as “indirect holders” of those securities. As we discuss below,
indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect
holders.
Book-Entry
Holders
We
may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities
may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary
on behalf of other financial institutions that participate in the depositary’s book-entry system. These participating institutions,
which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.
Only
the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form
will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will
recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary.
The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers
who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with
their customers; they are not obligated to do so under the terms of the securities.
As
a result, investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in
a global security, through a bank, broker or other financial institution that participates in the depositary’s book-entry
system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect
holders, and not holders, of the securities.
Street
Name Holders
We
may terminate a global security or issue securities in non-global form. In these cases, investors may choose to hold their securities
in their own names or in “street name.” Securities held by an investor in street name would be registered in the name
of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest
in those securities through an account he or she maintains at that institution.
For
securities held in street name, we will recognize only the intermediary banks, brokers and other financial institutions in whose
names the securities are registered as the holders of those securities, and we will make all payments on those securities to them.
These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they
agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street
name will be indirect holders, not holders, of those securities.
Legal
Holders
Our
obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only
to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities,
in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a
security or has no choice because we are issuing the securities only in global form.
For
example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even
if that holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect
holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us
of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes.
In such an event, we would seek approval only from the holders, and not the indirect holders, of the securities. Whether and how
the holders contact the indirect holders is up to the holders.
Special
Considerations For Indirect Holders
If
you hold securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should
check with your own institution to find out:
|
●
|
how
it handles securities payments and notices;
|
|
|
|
|
●
|
whether
it imposes fees or charges;
|
|
|
|
|
●
|
how
it would handle a request for the holders’ consent, if ever required;
|
|
|
|
|
●
|
whether
and how you can instruct it to send you securities registered in your own name so you
can be a holder, if that is permitted in the future;
|
|
|
|
|
●
|
how
it would exercise rights under the securities if there were a default or other event
triggering the need for holders to act to protect their interests; and
|
|
|
|
|
●
|
if
the securities are in book-entry form, how the depositary’s rules and procedures
will affect these matters.
|
Global
Securities
A
global security is a security that represents one or any other number of individual securities held by a depositary. Generally,
all securities represented by the same global securities will have the same terms.
Each
security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a
financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary.
Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, or “DTC,”
will be the depositary for all securities issued in book-entry form.
A
global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor
depositary, unless special termination situations arise. We describe those situations below under “Special Situations
When a Global Security Will Be Terminated.” As a result of these arrangements, the depositary, or its nominee, will
be the sole registered owner and holder of all securities represented by a global security, and investors will be permitted to
own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank
or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an
investor whose security is represented by a global security will not be a holder of the security, but only an indirect holder
of a beneficial interest in the global security.
If
the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security
will be represented by a global security at all times, unless, and until the global security is terminated. If termination occurs,
we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through
any book-entry clearing system.
Special
Considerations For Global Securities
The
rights of an indirect holder relating to a global security will be governed by the account rules of the investor’s financial
institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder
as a holder of securities, and instead, deal only with the depositary that holds the global security.
If
securities are issued only in the form of a global security, an investor should be aware of the following:
|
●
|
an
investor cannot cause the securities to be registered in his or her name, and cannot
obtain non-global certificates for his or her interest in the securities, except in the
special situations we describe below;
|
|
|
|
|
●
|
an
investor will be an indirect holder and must look to his or her own bank or broker for
payments on the securities and protection of his or her legal rights relating to the
securities, as we describe above;
|
|
|
|
|
●
|
an
investor may not be able to sell interests in the securities to some insurance companies
and to other institutions that are required by law to own their securities in non-book-entry
form;
|
|
●
|
an
investor may not be able to pledge his or her interest in a global security in circumstances
where certificates representing the securities must be delivered to the lender or other
beneficiary of the pledge in order for the pledge to be effective;
|
|
|
|
|
●
|
the
depositary’s policies, which may change from time to time, will govern payments,
transfers, exchanges and other matters relating to an investor’s interest in a
global security;
|
|
|
|
|
●
|
we
and any applicable trustee have no responsibility for any aspect of the depositary’s
actions or for its records of ownership interests in a global security, nor do we or
any applicable trustee supervise the depositary in any way;
|
|
|
|
|
●
|
the
depositary may, and we understand that DTC will, require that those who purchase and
sell interests in a global security within its book-entry system use immediately available
funds, and your broker or bank may require you to do so as well; and
|
|
|
|
|
●
|
financial
institutions that participate in the depositary’s book-entry system, and through
which an investor holds its interest in a global security, may also have their own policies
affecting payments, notices and other matters relating to the securities.
|
There
may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible
for the actions of any of those intermediaries.
Special
Situations When a Global Security Will Be Terminated
In
a few special situations described below, the global security will terminate and interests in it will be exchanged for physical
certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street
name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in
securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street
name investors above.
Unless
we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations
occur:
|
●
|
if
the depositary notifies us that it is unwilling, unable or no longer qualified to continue
as depositary for that global security and we do not appoint another institution to act
as depositary within 90 days;
|
|
|
|
|
●
|
if
we notify any applicable trustee that we wish to terminate that global security; or
|
|
|
|
|
●
|
if
an event of default has occurred with regard to securities represented by that global
security and has not been cured or waived.
|
The
prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular
series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not
we or any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.
PLAN
OF DISTRIBUTION
We
may sell or issue the shelf securities from time to time though any one or more of the following ways:
|
●
|
through
underwriters or dealers;
|
|
|
|
|
●
|
directly
to purchasers;
|
|
|
|
|
●
|
through
agents;
|
|
|
|
|
●
|
in
“at the market” offerings, within the meaning of Rule 415(a)(4) of the Securities
Act, to or through a market maker or into an existing trading market on an exchange or
otherwise; or
|
|
|
|
|
●
|
through
a combination of these methods.
|
Registration
of the shelf securities covered by this prospectus does not mean that the securities will be offered or sold.
Shelf
securities may be distributed from time to time in one or more transactions at a fixed price or prices, which may be changed;
at market prices prevailing at the time of sale; at prices related to such prevailing market prices; or at negotiated prices.
For
each offering of securities hereunder, we will describe the method of distribution of such securities, among other things, in
the applicable prospectus supplement. The prospectus supplement will set forth the terms of the offering of the securities, including,
as applicable:
|
●
|
the
name or names of any agents or underwriters;
|
|
|
|
|
●
|
the
amount of securities underwritten or purchased by any underwriter;
|
|
|
|
|
●
|
the
initial public offering price;
|
|
|
|
|
●
|
the
amounts of any commissions, discounts paid or allowed to any agents or underwriters;
|
|
|
|
|
●
|
the
proceeds we will receive;
|
|
|
|
|
●
|
any
other items constituting underwriters’ compensation;
|
|
|
|
|
●
|
any
discounts, commissions or concessions allowed or paid to dealers;
|
|
|
|
|
●
|
the
material terms of any agreement with any underwriters or agents; and
|
|
|
|
|
●
|
any
securities exchanges on which the securities may be listed.
|
Shelf
securities may be offered through underwriters. Any underwriter will be named, and any discounts allowed or other compensation
payable to any underwriter will be set forth, in the applicable prospectus supplement. The securities will be acquired by the
underwriters for their own account and may be resold from time to time in one or more transactions, including negotiated transactions,
at a fixed public offering price or at varying prices determined at the time of sale. The securities may be either offered to
the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Unless
otherwise set forth in the applicable prospectus supplement, the obligations of the underwriters to purchase the securities will
be subject to certain conditions precedent and the underwriters will be obligated to purchase all of the securities if any are
purchased. We may grant the underwriters an over-allotment option under which underwriters may purchase additional securities
from us. Underwriters may sell the securities to or through dealers, and such dealers may receive compensation in the form of
discounts, concessions or commissions from the underwriters or commissions from the purchasers for which they may act as agents.
Any initial public offering price and any discounts or concessions allowed or paid to dealers may be changed from time to time.
Shelf
securities may be offered to purchasers directly or through agents designated by us from time to time. Any agent involved in the
offer or sale of the securities will be named, and any commissions or other compensation payable by us to such agent will be set
forth, in the applicable prospectus supplement. Unless otherwise indicated in the prospectus supplement, any agent will be acting
on a best efforts basis for the period of its appointment.
Shelf
securities may be offered to purchasers through dealers as principals. The dealer may then resell the offered securities to the
public at varying prices to be determined by the dealer at the time of resale. The name of the dealer and the terms of the transaction
will be set forth in the applicable prospectus supplement.
Shelf
securities and resale shares may be offered into an existing trading market for such securities at other than a fixed price. Underwriters,
dealers, and agents who participate in any such at-the-market offerings will be named in the applicable prospectus, along with
the terms and conditions of any agency, marketing or similar agreement and the commissions payable or other compensation upon
sale of the securities.
We
may make direct sales of shelf securities through subscription rights distributed to our existing shareholders on a pro rata basis,
which may or may not be transferable. In any distribution of subscription rights to our shareholders, if all of the underlying
securities are not subscribed for, we may then sell the unsubscribed securities directly to third parties or may engage the services
of one or more underwriters, dealers or agents, including standby underwriters, to sell the unsubscribed securities to third parties.
Any underwriters, dealers or agents involved in the offer or sale of the securities will be named, and any commissions or other
compensation payable by us to such underwriter, dealer or agent will be set forth, in the applicable prospectus supplement.
We
may offer shelf securities directly to service providers or suppliers in payment of outstanding invoices.
Any
underwriters, broker-dealers and agents that participate in the distribution of the securities may be deemed to be “underwriters”
as defined in the Securities Act of 1933, as amended, or the “Securities Act.” Any commissions paid or any
discounts or concessions allowed to any such persons, and any profits they receive on resale of the securities, may be deemed
to be underwriting discounts and commissions under the Securities Act.
Agents
and underwriters may be entitled to indemnification by us against certain civil liabilities, including liabilities under the Securities
Act, or to contribution with respect to payments which the agents or underwriters may be required to make in respect of their
liabilities.
We
may authorize underwriters, dealers or agents to solicit offers by institutional investors, such as commercial banks and investment
companies, to purchase the shelf securities from us at the public offering price set forth in the applicable prospectus supplement
pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The terms and conditions
of these contracts and the commissions payable for solicitation of the contracts will be set forth in the prospectus supplement.
During
and after an offering through underwriters, the underwriters may purchase and sell the securities in the open market. These transactions
may include over-allotment and stabilizing transactions and purchases to cover syndicate short positions created in connection
with the offering. The underwriters may also impose a penalty bid, whereby selling concessions allowed to syndicate members or
other broker-dealers for the offered securities sold for their account may be reclaimed by the syndicate if such offered securities
are repurchased by the syndicate in stabilizing or covering transactions. These activities may stabilize, maintain or otherwise
affect the market price of the offered securities, which may be higher than the price that might otherwise prevail in the open
market. If commenced, these activities may be discontinued at any time.
Any
underwriters who are qualified market makers may engage in passive market making transactions in the securities in accordance
with Rule 103 of Regulation M.
Agents
and underwriters may be our customers, engage in transactions with us, or perform services for us in the ordinary course of business.
In
compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the aggregate maximum discount, commission
or agency fees or other items constituting underwriting compensation to be received by any FINRA member or independent broker-dealer
will not exceed 8% of any offering pursuant to this prospectus and any applicable prospectus supplement.
Unless
otherwise specified in the applicable prospectus supplement, shelf securities offered by us under this prospectus will be a new
issue and, other than the ordinary shares, which are listed on Nasdaq, will have no established trading market. We may elect to
list any other class or series of securities on an exchange, and in the case of the ordinary shares, on any additional exchange,
but, unless otherwise specified in the applicable prospectus supplement, we shall not be obligated to do so. Any underwriters
to whom securities are sold for public offering and sale may make a market in the securities, but the underwriters will not be
obligated to do so and may discontinue any market making at any time without notice. The securities may or may not be listed on
a national securities exchange or a foreign securities exchange. No assurance can be given as to the liquidity of the trading
market for any of the securities.
All
costs, expenses and fees associated with the registration and distribution of shelf securities will be borne by us.
EXPENSES
The following table sets
forth the costs and expenses payable by us in connection with registering the securities offered hereby. All amounts listed
below are estimates except the SEC registration fee.
Itemized expense
|
|
Amount
|
|
SEC registration fee
|
|
$
|
3,636
|
|
Legal fees and expenses
|
|
$
|
10,000
|
|
Accounting fees and expenses
|
|
$
|
15,000
|
|
Transfer agent and registrar fees
|
|
$
|
5,000
|
|
Miscellaneous
|
|
$
|
5,000
|
|
Total
|
|
$
|
38,636
|
|
Our costs and expenses
relating to each sale of securities being registered hereby will be provided by a prospectus supplement.
LEGAL
MATTERS
Graubard
Miller, New York, New York, is acting as counsel in connection with the registration of our securities under the Securities Act
and will pass upon pass upon certain legal matters for us with respect to the offering of our securities. HWL Ebsworth Lawyers,
Sydney, Australia, will pass upon the validity of the ordinary shares and preferred shares offered in this prospectus and on matters
of Australia law.
EXPERTS
The
financial statements incorporated in this prospectus by reference to the Annual Report on Form 20-F for the year ended
January 31, 2019 have been so incorporated in reliance on the report (which contains an explanatory paragraph relating to
Naked Brand Group Limited’s ability to continue as a going concern as described in Note 2 to the financial statements)
of PricewaterhouseCoopers, an independent registered public accounting firm, given on the authority of said firm as experts
in auditing and accounting.
SERVICE
OF PROCESS AND ENFORCEMENT OF CIVIL LIABILITIES
We
are an Australian company and our executive offices are located outside of the United States. Certain of our directors and officers
and some of the experts in this prospectus reside outside the United States. In addition, a substantial portion of our assets
and the assets of our directors, officers and experts are located outside of the United States. As a result, you may have difficulty
serving legal process within the United States upon us or any of these persons. You may also have difficulty enforcing, both in
and outside of the United States, judgments you may obtain in U.S. courts against us or these persons in any action, including
actions based upon the civil liability provisions of U.S. federal or state securities laws. Furthermore, there is substantial
doubt that the courts of Australia would enter judgments in original actions brought in those courts predicated on U.S. federal
or state securities laws.
WHERE
YOU CAN FIND ADDITIONAL INFORMATION
We
have filed with the SEC a registration statement on Form F-3 with respect to the securities offered hereby. This prospectus, which
forms a part of the registration statement, does not contain all of the information set forth in the registration statement and
the exhibits thereto. The registration statement includes and incorporates by reference additional information and exhibits. Statements
made in this prospectus concerning the contents of any contract, agreement or other document filed as an exhibit to the registration
statement are summaries of the material terms of such contracts, agreements or documents, but do not repeat all of their terms.
Reference is made to each such exhibit for a more complete description of the matters involved and such statements shall be deemed
qualified in their entirety by such reference. The registration statement and the exhibits and schedules thereto filed with the
SEC are available without charge on the website maintained by the SEC at http://www.sec.gov that contains reports, proxy and information
statements and other information regarding registrants that file electronically with the SEC.
We
are subject to the information and periodic reporting requirements of the Exchange Act and we file periodic reports, including
Annual Reports on Form 20-F, and other information, including reports on Form 6-K, with the SEC. These periodic reports and other
information are available on the website of the SEC referred to above. As a “foreign private issuer”, we are exempt
from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders under Nasdaq
rules. Those proxy statements are not expected to conform to Schedule 14A of the proxy rules promulgated under the Exchange Act.
In addition, as a “foreign private issuer”, we are exempt from the rules under the Exchange Act relating to short
swing profit reporting and liability.
INCORPORATION
BY REFERENCE OF CERTAIN DOCUMENTS
The
SEC allows us to incorporate by reference the information we file with it, which means that we can disclose important information
to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus.
This prospectus incorporates by reference our documents listed below:
|
●
|
our
Annual Report on Form 20-F filed with the SEC on June 14, 2019;
|
|
|
|
|
●
|
our
reports on Form 6-K filed with the SEC on February 11, 2019, February 15, 2019, March
28, 2019, April 3, 2019, May 17, 2019 and June 14, 2019; and
|
|
|
|
|
●
|
the
description of our ordinary shares contained in our registration statement on Form 8-A
(No. 001-38544) filed with the SEC pursuant to Section 12(b) of the Exchange Act.
|
We
are also incorporating by reference all subsequent Annual Reports on Form 20-F that we file with the SEC and certain subsequent
reports on Form 6-K that we furnish to the SEC (if such Form 6-K states that it is incorporated by reference into this prospectus)
after the effectiveness of the registration statement of which this prospectus forms a part, until we file a post-effective amendment
indicating that the offering of the securities made by this prospectus has been terminated. In addition, we are incorporating
by reference all subsequent Annual Reports on Form 20-F that we file with the SEC and certain subsequent reports on Form 6-K that
we furnish to the SEC (if such Form 6-K states that it is incorporated by reference into this prospectus) after the initial filing
of the registration statement, until the effectiveness of the registration statement.
Any
statement contained in a document filed before the date of this prospectus and incorporated by reference herein shall be deemed
to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein modifies or supersedes
such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute
a part of this prospectus. Any information that we file after the date of this prospectus with the SEC and incorporated by reference
herein will automatically update and supersede the information contained in this prospectus and in any document previously incorporated
by reference in this prospectus.
You
should assume that the information appearing in this prospectus and any accompanying prospectus supplement, as well as the information
we previously filed with the SEC and incorporated by reference, is accurate as of the dates on the front cover of those documents
only.
We
will provide to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the reports
or documents that have been incorporated by reference in the prospectus contained in the registration statement not delivered
with the prospectus. We will provide these reports or documents upon written or oral request at no cost to the requester. Requests
for such documents should be made to Naked Brand Group Limited, Attn: Mr. Justin Davis-Rice, c/o Bendon Limited, Building 7B,
Huntley Street, Alexandria, NSW 2015, Australia. Such documents may also be accessed free of charge on our website at www.bendon.com.
US$18,500,000
Ordinary
Shares
NAKED
BRAND GROUP LIMITED
Prospectus
Supplement
Maxim
Group LLC
September
24, 2020
Cenntro Electric (NASDAQ:NAKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cenntro Electric (NASDAQ:NAKD)
Historical Stock Chart
From Sep 2023 to Sep 2024